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ABSTRACT
The ARV Treatment Adherence Model:
A Qualitative Study on Antiretroviral (ARV) Treatment Adherence
for People Living with HIV
By
Danielle R. Strauss
Advisor: Alexis Kuerbis
Adherence to antiretroviral (ARV) treatment improves life expectancy and other health
outcomes for people living with HIV (PLWH). It also minimizes their risk of transmitting HIV
through sexual contact and is therefore a form of HIV prevention. However, many PLWH,
specifically low-income PLWH of color who have been disproportionately impacted by the
virus, face a multitude of barriers to ARV treatment adherence, making it much harder for them
to take their medication as prescribed and remain engaged in care. This qualitative study based
on Constructivist Grounded Theory explored the process by which 14 virally suppressed, lowincome PLWH of color overcame barriers to ARV treatment adherence to achieve viral
suppression. Data analysis revealed four factors that helped facilitate ARV treatment adherence.
1) Access to inclusive, nonjudgmental and destigmatizing quality medical care administered by
culturally competent medical providers. 2) Trust in medical provider, the medical system, and
medication. 3) Self-efficacy to accept the chronic medical condition and need to take medication
to control it, be actively engaged in medical care, and take medication as prescribed. 4)
Motivation, or having a will to live, something to live for (a life goal), a desire to be healthy and
not be sick, and to not transmit HIV to others. These findings informed an emerging theory about
ARV treatment adherence called the ARV Treatment Adherence Model. HIV policy and medical
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and social service providers interested in improving viral suppression rates for PLWH would
benefit from developing interventions that minimize the competing barriers and reinforce the
facilitators of ARV treatment adherence highlighted by the ARV Treatment Adherence Model.
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Chapter 1. Introduction and Background

Knit your hearts with an unslipping knot.
--William Shakespeare, Antony and Cleopatra, 1623

Adherence to antiretroviral (ARV) treatment improves life expectancy and other health
outcomes for people living with HIV (PLWH). Adherence to the medication, or the extent to
which they take the medication as prescribed by a medical provider, leads to viral suppression
(having <200 copies or viral load), which stops the virus from multiplying and decreases the
amount of virus in their system. Consistent and sustained adherence results in an undetectable
(<20 copies) status, which means there is so little virus in their system that it cannot be detected
by a lab test. It also means that the virus cannot be transmitted to other people through sexual
contact (CDC, 2018). Thus, consistent adherence to ARV treatment is primary prevention for
HIV. However, many PLWH, specifically low-income PLWH of color who have been
disproportionately impacted by the virus, face a multitude of barriers to ARV treatment
adherence, making it much harder for them to take their medication as prescribed and remain
engaged in care. This qualitative study based on Constructivist Grounded Theory explored the
process by which virally suppressed, low-income PLWH of color overcame barriers to ARV
treatment adherence to achieve viral suppression. The findings from the study can be used to
inform HIV policy and medical and social service practice on strategies that facilitate ARV
treatment adherence for low-income PLWH of color.
According to the CDC, if at least 90% of PLWH were undetectable, the United States
could end the HIV epidemic by 2030 (CDC, 2018, HHS, 2019). Current U.S. federal policy on

1
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HIV aims to prevent new HIV infections, improve HIV-related health outcomes for PLWH,
reduce HIV-related disparities and health inequities, and achieve integrated and coordinated care
that addresses the HIV epidemic among all communities and sub-populations (The White House,
2021). The focus on the need to reduce HIV-related disparities and health inequities is not new to
HIV federal policy, but it has received particular attention in recent years. The recent focus is in
recognition of the disproportionate impact of the virus on specific populations of color.
According to the CDC, people who identify as Black/African American accounted for 42% of all
new HIV diagnoses in 2018 despite only making up 13% of the total U.S. population. People
who identified as Hispanic/Latinx accounted for 29% of new HIV diagnoses in 2019 despite
comprising only 18.5% of the U.S. population (CDC, 2020). The proportions are more striking
for low-income PLWH in the United States. According to the 2020 Annual Ryan White Clientlevel Data Report1, Ryan White clients who are HIV positive and low-income based on
eligibility criteria to receive Ryan White services, who identified as Black or African American
comprised nearly half (46%) of the PLWH who received Ryan White services since 2016. Ryan
White clients living with HIV who identified as Hispanic or Latinx comprised 23-24% of the
Ryan White population consistently since 2016 (HRSA, 2021).
The Ryan White Annual Report further reports the viral suppression rates for its
population of PLWH, by race and ethnicity. While the overall rate of viral suppression among
Ryan White clients living with HIV in 2020 was 89.4%, for Ryan White clients who identified as

1

The Ryan White Comprehensive AIDS Resources and Emergency (CARE) Act was passed by the U.S.
Congress in 1990. Since then, it has authorized the federal government to allocate federal funding to local
constituencies to combat the spread of HIV and help care for low-income PLWH. The Ryan White Client-level Data
Report is an annual report published by the federal government on the demographics of clients who receive Ryan
White Services. (HRSA, 2021).
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White, 92.5% were virally suppressed in 2020, compared to 86.7% of the Ryan White clients
who identified as Black/African American. Interestingly, the viral suppression rate for the Ryan
White Hispanic/Latinx population was on par with their White counterparts (HRSA, 2021). At a
more local level, however, the viral suppression rates for Black/African Americans and
Hispanic/Latinx PLWH from New York State was lower than the national rate. While the overall
viral suppression rate for the state was 75% in 2020 (of PLWH diagnosed with HIV), 80% of
PLWH from NYS who identified as White were virally suppressed in 2020, compared to 72% of
Black/African American and 76% of Hispanic/Latinx PLWH from New York State (AIDS
Institute, NYS Department of Health, 2021).
The New York City Department of Health and Mental Hygiene (DOHMH) has tracked
and monitored HIV/AIDS surveillance data for New York City and surrounding areas since the
beginning of the epidemic. New York City has shown great promise over the past 20 years in its
effort to achieve the federal goal of ending the epidemic by 2030. There was a 76% decrease in
new HIV diagnoses in New York City since 2001, and a 29% decrease from 2016 to 2020 (HIV
Epidemiology Program, 2021). In fact, by 2018, the number of new HIV cases fell below 2000
for the first time since the beginning of the epidemic (NYC DOHMH, 2019). The DOHMH
surveillance report further indicates that in 2020, 86% of all PLWH from NYC were virally
suppressed. However, only 70% had sustained viral suppression, meaning they maintained a
consistent viral suppression rate over the course of at least 14 months (HIV Epidemiology
Program, 2021). Similar to state and national levels, there was a disparity in viral suppression
and sustained viral suppression rates for NYC by race and ethnicity. While 83% of
Black/African Americans and 87% of Latinx/Hispanics were virally suppressed in 2020,
compared to 93% of their White counterparts, 64% of Black/African Americans and 70% of
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Hispanic/Latinx were able to maintain sustained suppression, compared to 84% of their White
counterparts (HIV Epidemiology Program, 2021).
Consistent with the data from the Ryan White Client-level Data Report indicating that
people of color from lower socio-economic groups are disproportionately impacted by HIV, the
NYC Human Resource Administration (HRA) collects data on PLWH from NYC who are low
income and therefore eligible for HIV/AIDS Service Administration (HASA) financial benefits.
This is enhanced public assistance for poor PLWH in New York City (NYC HRA, 2018). In
March 2018, Black/African Americans and Hispanics/Latinx comprised 86% of people eligible
for HASA benefits in NYC. Of those who were eligible for HASA benefits in March 2018, 8%
(N=3,781) were homeless (NYC HRA, 2018), compared to 3% of the homeless population with
HIV nationwide (National Alliance to End Homelessness, 2019). An additional 10% (N=4,697)
of low-income PLWH from NYC had histories of homelessness and were living in supportive
housing for PLWH (NYC HRA, 2018).
The racial and socio-economic disparities in the HIV/AIDS epidemic have been
documented in numerous studies on HIV/AIDS across the country. In a large study on HIV
incidence rates conducted in 80 US cities with populations greater than 100,000, researchers
found that for heterosexuals, poverty and racism were the most significant factors that predicted
HIV risk behavior. For sexual minority men (SMM), the most significant factors were stigma
and discrimination (Buot, et al. 2014). Among SMM, Wejnert et al. (2016) found that although
African American SMM in their study did not report greater sexual risk compared to their White
counterparts, they were significantly more likely to acquire HIV at younger ages and were
significantly less likely to be aware of their status. These researchers suggested that the disparity
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was due to structural barriers in the Black community that increased their risk of HIV, such as
unemployment, low-income, incarceration, lack of education, and reduced access to care.
With regard to housing as a structural barrier, Aidala et al. (2016) conducted a systematic
review of 152 studies, consisting of two randomized control trials, 64 prospective studies, 6
retrospective studies, and 3 case-control studies. They found that for PLWH who were homeless
at the time of the studies, housing instability was associated with poorer health outcomes,
inconsistent healthcare utilization, and higher rates of HIV risk behavior compared to PLWH
who were not homeless. Similarly, reviewing HIV/AIDS surveillance data collected by the CDC,
Kidder et al. (2007) compared health outcomes and healthcare utilization of a cohort of PLWH
enrolled in a cross-sectional, multi-site study. They found that PLWH who were homeless,
compared to those who were not homeless, reported significantly more days in the past 30 days
during which they were physically ill, suffered from mental health symptoms, or were limited in
their ability to perform daily tasks due to not feeling well.
De Jesus (2019) explains that despite advancements in HIV treatment, the public health
goal of ending the epidemic in the US will not be achieved without addressing the social
determinants of health that disproportionately affect low-income PLWH. These include access to
adequate housing, quality healthcare and health insurance, childcare, education, and employment
(De Jesus, 2019). The Professional Association of Social Workers in HIV/AIDS (PASHWA)
agrees. In a Public Comment in response to the Federal policy to end the epidemic, PASHWA
issued a statement criticizing the national policy for relying entirely on bio-medical interventions
and not doing enough to address the psychosocial factors that impede ARV treatment, such as
mental health and wellness (PASHWA, 2019).
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As a result of the lack of attention and funding to address the structural and psychosocial
barriers to ARV treatment adherence, low-income PLWH of color are less likely to be virally
suppressed, more likely to spread the virus to others, and have worse survival rates compared to
other PLWH. However, despite the abundance of factors hindering their ability to adhere to their
medication, at least 83% of African Americans and 87% Hispanic/Latinx PLWH were virally
suppressed in NYC in 2020 (HIV Epidemiology Program, 2021). Therefore, the aim of this
qualitative study based on Constructivist Grounded Theory was to unpack the process associated
with ARV treatment adherence for a group of virally suppressed, low-income PLWH of color
from NYC, in order to generate theory that informs the field and sheds light on the strategies that
helped them overcome the structural and psychosocial barriers to treatment adherence to achieve
viral suppression. The research questions explored by this study include:
1) What was the process by which low-income PLWH of color from NYC became virally
suppressed through ARV treatment adherence?
2) What motivated them to become virally suppressed?
3) What barriers did they perceive to ARV treatment adherence?
4) How did they overcome these barriers?
The next chapter reviews the empirical and theoretical literature on ARV treatment
adherence, culminating with a summary of what is currently known or understood about the
factors that both impede and help facilitate ARV treatment. Following the Literature Review is
the Methodology chapter. This chapter describes the qualitative methods employed by this study
based on Constructivist Grounded Theory. The chapter includes the data collection and analysis
process used to generate the findings. Following the Methods chapter is the Findings chapter
which details the findings from the qualitative study. The findings informed the theory that
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emerged from the data to help explain the process for successful ARV treatment adherence for
low-income PLWH of color. This theory is presented in the final Discussion chapter. This
chapter also summarizes the findings within the context of their implications for HIV policy and
medical and social service intervention, noting the limitations of the study and recommendations
for future research.
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Chapter 2. Review of the Literature
This chapter contains a review of the literature on ARV treatment adherence. It focuses
on the empirical research that highlights what is currently known and understood about the
multitude of barriers to ARV treatment adherence. This is followed by a section that summarizes
the theoretical literature on the subject, which covers the theories and models that have been
applied to ARV treatment adherence, as well as medication adherence for chronic medical
conditions in general.
Empirical Literature on ARV Treatment Adherence
In order to end the HIV/AIDS epidemic, at least 90% of PLWH need to adhere to their
medication in order to become virally suppressed (CDC, 2018). This review of the empirical
literature examines the research studies that have been conducted to understand the factors that
both facilitate and impede ARV treatment adherence. The section is divided into subsections by
barrier to treatment. The first subsection reviews the structural barriers caused by poverty and a
fractured healthcare industry that have impeded access to quality medical care and the continuity
of care. This is followed by a subsection on HIV stigma and systemic racism. After this
subsection are the subsections explaining the personal and behavioral factors that impact ARV
treatment adherence, such as substance use and mental health.
Structural Barriers to ARV Treatment Adherence
Structural barriers to ARV treatment adherence from within the healthcare industry have
been well documented in the literature. In 2011, Mugavero et al. conducted a study grounded in
the socio-ecological model that revealed fragmentation in the healthcare system for PLWH
despite the policy claims of a continuum of care. Their study presented evidence of how
surveillance data collected by health departments were not being shared at the provider level. As
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a result, providers were unaware of how the virus was spreading within their communities or
which groups were at particularly high risk. In addition, HIV testing sites were not successfully
linking people who tested positive for HIV to care and treatment. While the researchers
acknowledged that supportive services at the institutional level existed for PLWH, such as case
management services, housing assistance, and transportation, their study revealed that these
programs were underfunded and not offered consistently across the country. Finally, at the policy
level, their study highlighted a disconnect between the CDC, which was responsible for
regulating HIV testing and prevention activities, and HRSA, which provided guidance and
monitoring of HIV care and treatment facilities. They concluded with a recommendation for
improved synergies between public, private and nonprofit funding and service agencies
responsible for the provision of all aspects of the HIV care continuum in order to mitigate the
structural barriers to HIV care and treatment (Mugavero, et al., 2011).
Other researchers also used the socio-ecological framework to uncover structural barriers
impacting ARV treatment adherence. Castro et al. (2015) explored the barriers and facilitators of
ARV treatment adherence among PLWH in Puerto Rico. This was a qualitative study that
involved 12 in-depth interviews with HIV patients with a reported history of poor treatment
adherence. The findings from this study revealed a variety of themes to explain barriers to
treatment adherence from the perspective of the study participants. Specifically, regarding the
structural barriers, the study revealed that at the higher systems and macro-level, the participants
explained that interruptions in their medication adherence were sometimes caused by health
insurance companies not approving their medications in time or pharmacies running out of the
medication. In addition, at this level, the participants spoke of real and perceived stigma and
discrimination from medical providers, members of their communities and family members,
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which sometimes caused them to not take their medications because they felt shame or were
trying to hide it from others.
Kalichman et al. (2017) further explored the impact of structural barriers on ARV
treatment adherence in their study of 556 severely and moderately non-adherent HIV positive
adult men and women from Atlanta, GA. Severely non-adherent to ARV treatment was defined
as having taken < 75% of their prescribed ARV medications over the past 30 days and
moderately non-adherent was defined as having taken 75-95% of their prescribed medication for
the same time period. Ninety-three percent of the participants identified as African American and
65% identified as low-income (earned <$10,000/yr.). The results of their study found that both
substance use and structural barriers, such as running out of their medications, being unable to
get to a pharmacy, or being unable to afford their medication, were the primary factors that were
significantly associated with being severely non-adherent to their ARV medication. Similarly,
Surratt, et al. (2015) examined the impact of food and housing insecurity on medication
adherence among indigent HIV positive substance users from South Florida. Food and housing
insecurity was reported by nearly half (43.3%) of the participants of this study. In addition to
being significantly more likely to have severe psychological distress and substance dependence,
the food/housing insecure cohort of participants were significantly more likely to not adhere to
their ARV treatment as prescribed, be less engaged in medical care, and have a less favorable
attitude about their medical provider.
In an effort to minimize the structural barriers to ARV treatment adherence, Ghose et al.
(2019) conducted a mixed-method evaluation of an intervention that offered financial incentives
(a $100 gift card up to 4 times per year) to PLWH to motivate them to achieve and maintain viral
suppression. Of the 502 participants who participated in the quantitative component of the
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evaluation, 71% identified as African American and 20% identified as Latinx. In addition, 50%
had a mental health diagnosis at baseline, 63% used illicit drugs and 60% had experienced
homelessness during the course of the study period. The results of the quantitative component
revealed that there was a 17% increase from baseline to post intervention follow-up in the
proportion of participants who were virally suppressed. African Americans and homeless clients
were 50% less likely to be virally suppressed at baseline, compared to their counterparts. But
African Americans and substance users were twice as likely as their counterparts to have
experienced an effect from the intervention (become virally suppressed as a result of the
financial incentive), suggesting that these populations were in greater need of the financial
assistance than the other groups. Findings from the qualitative component of the Ghose et al.
(2019) study, which engaged 30 graduates of the intervention in semi-structured exit interviews,
revealed that the provision of the financial incentive increased ARV Treatment adherence by
increasing the value of viral suppression and providing motivation to achieve it and maintain it
over time. According to the qualitative findings, participants were able to sustain adherence by
being more motivated to seek healthcare, less in desperate need of money that sometimes lead
them selling their medication on the black market, and more engaged in supportive services that
linked them to housing, drug treatment, and other programs (Ghose, et al., 2019).
HIV Stigma and Systemic Racism
The impact of HIV stigma on ARV treatment adherence as a structural barrier to ARV
treatment is also well documented in the literature. Earnshaw et al. (2013) applied the HIV
Stigma Framework to a sample of 95 PLWH recruited from a clinic in the Bronx. The results of
this study suggested that internalized stigma (applying negative feelings and beliefs associated
with HIV to oneself) was significantly associated with feelings of helplessness and poor ARV
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treatment adherence. Similarly, Bennett et al. (2016) conducted a study of 88 youth living with
HIV from Philadelphia. The purpose of this study was to examine the relationship between
perceived HIV-related stigma, shame, and avoidant coping with internalized symptoms, such as
depression, anxiety and PTSD. The results revealed that HIV-related stigma and avoidant coping
were significantly associated with feelings of depression and PTSD, but not anxiety.
Turan et al. (2017) developed a conceptual framework to depict the relationship between
stigma and HIV-related behavior based on the theory that individuals living with stigmatized
identities have worse health outcomes. They adapted the Minority Stress Model, a conceptual
framework developed by Meyer (2003) to explain the effects of minority sexual orientation on
mental health, to PLWH based on the justification that all marginalized groups experience more
social stress than their counterparts because of their minority social position. This in turn has a
negative impact on their health. The adapted framework factored in the effects of structural
stigma (experiences of HIV discrimination, perceived HIV stigma from one’s community,
anticipated HIV stigma, and internalized HIV stigma) on engagement in medical care, retention
in care, and health outcomes (e.g. viral suppression). Turan et al. (2017) further considered the
effects of intersectional stigmas, such as race, class, gender, and sexuality. They theorized that
HIV-related stigma contributed to enhanced stress and other mental health factors, which
contributed to poorer health-related behaviors. They suggested that HIV-related stigma
contributed to poorer engagement in care behaviors due to perceptions that better, more qualified
health professionals would choose to specialize in diseases that were less stigmatized, or work in
more affluent neighborhoods. Finally, the researchers proposed that due to HIV-related stigma,
PLWH chose not to engage in care at HIV specific clinics because they would not want to be
seen there. These researchers offered recommendations for further research on the relationship

Running Head: ARV Treatment Adherence Model

13

between stigma and HIV-related health behavior, suggesting that a closer look at the
intersectionality of the experience of multiple stigmas impacting this population is needed, which
might also highlight protective factors, such as social support and coping strategies, that emerge
from the individuals’ other identities (Turan, et al. 2017).
Finally, Li, et al. (2018) conducted a mixed-method, community-based research project
called the Community Champions HIV/AIDS Advocates Mobilization Project (CHAMP). The
goal of this project was to reduce HIV stigma and mobilize champions to address HIV stigma in
the African/Caribbean, Asian and Latino communities in Toronto, Canada, by engaging
participants in two group interventions that addressed HIV/AIDS stigma: Acceptance and
Commitment Therapy/Training (ACT) and Social Justice Capacity Building (SJCB). Participants
were randomly assigned to the experimental group which received both group interventions or
the control group that received just the SJCB intervention. The results of the study revealed that
the experimental group that received ACT had significantly decreased their internalized HIV
stigma more compared to the control group. These findings were sustained at 9-month follow up.
The researchers suggested that as a result of having decreased HIV stigma, the participants of the
project had improved mental health symptoms and overall well-being, which lead to better
engagement in medical care and ARV treatment adherence (Li, et al. 2018).
Regarding systemic racism, African Americans have a long history of poor engagement
in healthcare and a lack of trust in the medical industry, due to systemic racism in the field. This
stems from their unique history of discrimination, oppression, and exploitation, going back as far
as slavery and including the Tuskegee Syphilis Study (Gaston & Alleyne-Green, 2013). Gaston
and Alleyne-Green (2013) conducted a systematic review of the literature regarding this topic in
a two-step process. The first step was to identify articles that met their inclusion criteria: 1)
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published articles from peer-reviewed journals from 2001 to 2012, 2) articles that focused on
ARV treatment adherence and/or medical self-care, and 3) studies that recruited HIV-positive
African American adult men or women. Studies were excluded if the results did not separate out
by race. A total of 326 studies met the criteria. The second step was to consider only those
studies that included perceptions about HIV medical care in relation to medical self-care and/or
perceptions of HIV medical care in relation to ARV treatment adherence. Medical self-care was
defined as going to the doctor as scheduled, regular contact with provider, and taking care of
one’s health through good nutrition and exercise. Sixteen of the 326 studies met the criteria and
were included in the final qualitative analysis (Gaston & Alleyne-Green, 2013).
Findings from this review revealed three key themes with regard to factors that impacted
African Americans’ perceptions about HIV medical care. These were 1) perceived racism and
discrimination within healthcare settings, 2) conspiracy beliefs, and 3) perceived quality of their
relationship with their healthcare provider (Gaston & Alleyne-Green, 2013). Specifically,
perceived racism and discrimination within the healthcare setting was reported as a barrier to
medical self-care among the African Americans with HIV engaged in these studies. Several
studies found correlations between the existence of conspiracy beliefs about HIV and HIV
treatment with lower rates of ARV treatment adherence and poorer health outcomes. Conversely,
a good relationship with and trust in one’s healthcare provider was associated with better
treatment adherence and health outcomes.
Consistent with the above review, Mattocks et al. (2017) conducted a qualitative study
that involved 32 semi-structured interviews with African American Veterans with HIV. The
purpose of this study was to assess HIV conspiracy beliefs and mistrust in physicians providing
HIV care among African Americans. This study was based on the belief that the African
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American community in general is suspicious of government and medical providers, which
contributes to the health disparities in the racial groups. The mean age of the study sample was
55 and 90% were male. Nearly half (44%) had been homeless at some point in their lives, 22%
had histories of depression and most reported active substance use. Sixty-nine percent of the
participants were on ARV treatment at the time of the study (Mattocks, et al., 2017).
Five major themes were found in this qualitative study which seemed to confirm the
belief that African Americans held conspiracy theories about HIV and the government. Many of
the veterans in the study believed strongly that HIV was a disease created by the government to
control poor and minority populations. They also believed that pharmaceutical companies had a
cure for the virus but were withholding it in order to preserve their profits. They further believed
that some people with money and fame, such as Magic Johnson, had already received the cure.
Some of the veterans believed that their doctors at the VA hospital were not aware of the cure
that the pharmaceutical companies were withholding because they believed that if the doctors
knew about it, they would share it with them. However, other veterans believed that the
physicians were in on the secret. Finally, the veterans were skeptical that HIV treatment was
helpful and believed that the medication sped the progress of the virus to AIDS and eventually
death. These veterans admitted to lying to their doctors about taking their medication (Mattocks,
et al., 2017).
Substance Use’s Impact on ARV Treatment Adherence
With a particular interest in the relationship between substance use behaviors and ARV
treatment adherence, Nicholas et al. (2014) conducted a secondary analysis of data collected
from a large, multi-national, randomized controlled trial that involved 775 participants living
with HIV from 14 sites in Africa (15.4%), Puerto Rico (12.6%) and the United States (72%). The
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sample was majority male (59%) and African national or African American (43.6%), followed
by Hispanic/Latinx (27.8%). Most (70.9%) of the participants reported that they had completed
high school, and 78.2% reported that they were low-income. The results revealed a significant
association between substance use and lower engagement in HIV care and poorer adherence to
ARV treatment.
Similarly, Parsons et al. (2014) studied patterns in the types and frequency of substance
use, and its association with ARV treatment adherence, among a group (n=557) of older adults
(50+) living with HIV from NYC. The majority (40.4%) of this group were men who identified
as Gay/Bisexual, followed by heterosexual men (28.1%), heterosexual women (26.7%) and
women who identified as Lesbian/Bisexual (4.9%). Over two-thirds (68.6%) of the sample
identified as Black/African American, followed by Latinx (17.4%), and White (11.3%). While
the results from this study were consistent in terms of identifying a significant relationship
between substance use and poor ARV treatment adherence, deeper analysis revealed no
significant relationship with regard to substance type or frequency of use.
Another study aimed at identifying psychosocial factors that influence ARV treatment
adherence among HIV positive substance users from Vancouver, Canada. The sample for this
study consisted of 667 participants, of which two-thirds were male and slightly less than half
were non-White (Lee, et al. 2016). Multivariate analysis of the data revealed a significant
positive association between self-efficacy and enrollment in a methadone maintenance program
with 95% or greater ARV treatment adherence. Factors that were negatively associated with
ARV treatment adherence included the belief that the ARV medication would make them feel
sicker (either due to side effects or from the treatment itself) and active substance use (Lee, et al.
2016).
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Finally, Feldman et al. (2019) investigated the relationship between drug use patterns and
viral suppression rates among a cohort of PLWH from New York City who were engaged in a
Ryan White funded support service. The sample consisted of 7,896 PLWH who completed at
least three assessments over the course of a three-year period. The majority of the sample was
male (61%), African American (57%), and living below 100% of the federal poverty level
(83%). In addition, 28% reported that they were unstably housed at baseline. About one third
(33.9%) reported a history of substance use, of which crack/cocaine was the most common
substance of choice (46%). Consistent with the previous studies, the researchers found a
significant relationship between active substance use, including those who reported only
occasional use, with having an unsuppressed viral load (Feldman, et al., 2019).
Personal and Psychosocial Factors that Influence ARV Treatment Adherence
The Castro et al. (2015) study revealed several psychosocial factors that interfered with
ARV treatment adherence. These were primarily found at the individual level of the socioecological framework and included fear of negative side effects from the medications, mental
health issues, and feelings of being healthy and therefore not needing treatment. At the
interpersonal level, the primary themes revealed by this study were a lack of social support in
general and negative influences from peers, in particular. Finally, the Castro et al. (2015) study
revealed themes found at the individual level of the framework that were labeled as facilitators of
treatment adherence. These included a desire to live, as well as a desire to not feel sick, meaning
that once the participants experienced symptoms of illness, they were more motivated to adhere
to their treatment to feel better.
In another study that focused on psychosocial factors that influenced ARV treatment
adherence, van den Berg et al. (2016) examined the interrelationships between psychosocial
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factors such as personal resources (social support, healthcare provider relationship, and HIV
treatment knowledge), contextual/environmental factors (stigma and trauma), and intrapersonal
factors (depressive symptoms), with ARV treatment adherence among PLWH in the US. Their
study sample was disproportionately male (93.1%) and white (71.1%). Nevertheless, they found
that ARV treatment adherence was significantly associated with a positive relationship with
one’s healthcare provider and negatively impacted by experiences of depression and trauma (van
den Berg, et al. 2016).
Similarly, Tatum and Houston (2017) explored the relationship between depressive
symptoms, intrinsic and extrinsic motivation, and ARV treatment adherence, with self-efficacy
as a mediating factor. The researchers selected participants from two small cross-sectional
studies. The first one looked at the relationship between treatment perceptions, mental health and
ARV treatment adherence among a sample of 85 low-income urban women. The second study
considered the relationship between treatment perceptions and motivation among 39 men.
Combined, the sample was predominantly African American (84%) and female (68%). The
results of the study revealed that when examined together, self-efficacy fully mediated the
relationship between the predictor variables (both types of motivation and depressive symptoms)
with ARV treatment adherence (Tatum & Houston, 2017). In other words, the researchers found
that self-efficacy to adhere to ARV treatment can minimize the negative impact of depressive
symptoms or low motivation on ARV treatment adherence.
In another study conducted by Kalichman et al. (2016), the researchers wanted to identify
factors that would predict ARV treatment adherence beyond the structural barriers associated
with poverty. The sample consisted of 942 PLWH from Atlanta, Georgia. Over the course of a
six-week period, the participants completed a computer-assisted baseline survey plus three
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follow up phone calls that addressed their treatment adherence. In addition, participants provided
urine samples for drug screening, as well as medical documentation of their most recent HIV
viral load and CD4 cell count results. The researchers found that the participants who were less
than 85% adherent to their medications were significantly more likely to exhibit poorer physical
health outcomes, more symptoms of depression, and greater substance use; however, none of
these variables alone were significant predictors of poor ARV treatment adherence. When
structural barriers associated with poverty, such as unstable housing, food insecurity and a lack
of transportation, were added to the model, they too were significant predictors of poorer
treatment adherence, but again no single factor emerged as a significant independent predictor.
Other factors identified as significant predictors of poor ARV treatment adherence were the
participants’ belief that taking the medication was not necessary, concerns about side effects of
the medication, the cost of the medications, and how taking the medication interfered with other
aspects of their lives (Kalichman, et al. 2016). Thus, while numerous factors had a significant
negative impact on ARV treatment adherence, this study highlights that most factors were only
significant in combination with other factors, suggesting that it is a combination of factors that
influence ARV treatment adherence, requiring a multipronged approach to intervention.
Finally, in a mixed-method, systematic review, Mey et al. (2017) identified factors that
influence PLWH in Australia in making decisions regarding being tested, initiating medical care,
and long-term treatment adherence. Seventy-two studies (all Australian) were included in the
review; 34 employed quantitative methods; 30 employed qualitative methods, and six were
mixed-methods studies. Quantitative studies addressed demographics; participant knowledge,
attitudes and beliefs about HIV; ARV treatment outcomes; patterns of associations between the
intrapersonal variables; and treatment initiation and adherence behaviors. The qualitative studies
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offered insight into the participants’ lived experience with regard to HIV-related health behavior,
specifically related to motivation and barriers to treatment uptake and adherence. Slightly more
than half of the studies (n=42) included PLWH as a group, whereas 16 of the studies involved
sexual minority men (SMM) with HIV exclusively. The others looked at aboriginal groups and
immigrants with HIV. Consistent with the demographic profile of PLWH in Australia, the
majority of the participants were SMM and had lived with the HIV virus for at least 12 months.
Their socio-economic status ranged from low income to high income.
The results of the systematic review revealed that while the majority of the studies
reported that the participants believed ARV treatment to be effective at suppressing the virus
within their systems and thus improving their health outcomes, they were skeptical that the
treatment would reduce or eliminate HIV transmission (Mey, et al., 2017). They also expressed
concerns about real and perceived long-term side effects of ARV treatment, such as the toxicity
of the medication. Regarding stigma, the vast majority of participants reported some experience
with discrimination from multiple sources, including healthcare providers. Many reported having
co-morbidities, such as mental illness and substance use, which required multiple and sometimes
conflicting medication regimens and intolerable side effects. However, according to the
researchers, the factors that seemed to have the highest correlation with ARV treatment
adherence were lack of knowledge, skepticism about the effectiveness of the treatment, fear of
side effects from the medication, and substance use.
The qualitative studies revealed a network of interrelated themes that centered on
emotional and physical challenges related to the virus, compounded by other factors related to
other health-related behaviors (Mey, et al., 2017). Many of the participants described their
diagnosis as shocking and traumatic. They talked about the need to come to terms with a
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different future for themselves that involved having to be on medication for the rest of their lives,
and the sadness and fear of death associated with the diagnosis. Regarding their fear of side
effects, the participants discussed concerns about not being able to fulfill their other
responsibilities if they had debilitating side effects to the medication. Others reported adhering to
medication meant they were surrendering to the HIV. Still others reported they simply felt better
and healthier when they were not on the medication. Finally, the researchers concluded their
extensive systematic review with a recommendation for more research to understand how the
lived experience of having HIV and ARV treatment adherence contributes to understanding the
rationales for how they manage their disease.
Summary of the Empirical Literature on ARV Treatment Adherence
The review of the empirical literature on ARV treatment adherence revealed that PLWH,
specifically PLWH of color and of lower socio-economic status, face a myriad of structural,
behavioral and personal barriers that impede their ability to adhere to ARV treatment as
prescribed. Inconsistent ARV treatment adherence contributes to their poorer health outcomes
and reduced rates of viral suppression that make the goal of ending the HIV epidemic harder to
achieve. Research on the subject suggests that structural barriers, such as poverty, housing
instability, access to quality healthcare and medication, as well as access to high quality medical
providers, significantly impact PLWH’s ability to maintain consistent ARV treatment adherence.
HIV-related stigma and systemic racism within the healthcare industry have also created barriers
to treatment for this vulnerable population. Finally, active substance use appears to be a
significant behavioral barrier to ARV treatment adherence as well as numerous other
psychosocial factors, such as mental illness and trauma.
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While the barriers are numerous, the empirical literature did reveal a few factors that
facilitated ARV treatment adherence among low-income PLWH of color. Self-efficacy regarding
one’s ability to adhere to their medication and the belief that the medication is effective appear to
be strong predictors of ARV treatment adherence. In addition, financial incentives appear to
function as strong motivators with regard to ARV treatment adherence for low-income PLWH.
Finally, a good relationship with one’s healthcare provider was a factor that helped facilitate
ARV treatment adherence. The next section reviews the theoretical literature regarding ARV
treatment adherence, exploring the field’s current understanding about the importance of these
key facilitators of ARV treatment adherence in greater depth.
Theoretical Literature on ARV Treatment Adherence
A review of the theoretical literature on ARV treatment adherence revealed that Social
Cognitive Theory was applied most often as a framework for understanding the factors that help
facilitate ARV treatment adherence. Social Cognitive Theory considers the interactions between
personal, behavioral and environmental factors that influence and explain human behavior.
Personal factors include knowledge, expectations, and attitudes about a specific behavior.
Behavioral factors include one’s ability (or self-efficacy) to change behavior, such as whether
one has the skill and belief in their ability to change. Environmental factors address social norms
about the behavior, influence from others from the community, and access to resources
(Bandura, 2018). Brown et al. (2013) examined the correlation between the above factors
identified by Social Cognitive Theory and ARV treatment adherence for PLWH. They found a
significant correlation between behavioral factors, such as self-efficacy, personal factors, such as
one’s knowledge and expectations about ARV treatment, with actual ARV treatment adherence
behavior. Nokes et al. (2012) similarly found that self-efficacy was both a direct predictor of
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ARV treatment adherence, as well as a moderating factor that mitigated the negative influences
from the environment and depressive symptoms. However, neither of these studies explored in
depth the relationship or impact of the environmental factors on ARV treatment adherence.
The Andersen Health Behavioral Model has also been applied to ARV treatment
adherence. This theory explains how health-related behavior is influenced by predisposing,
enabling and need factors. The predisposing factors include demographic, socio-economic and
personal factors about a patient. In other words, they are factors that predispose a patient to
utilize healthcare. Enabling factors are resources that help facilitate healthcare access and
utilization, such as community-based services, transportation, and having access to health
insurance. Finally, need refers to how the patient perceives their health status and need for
healthcare (Hong, et. al, 2019). In the context of ARV treatment adherence, Petrovic and Blank
(2015) applied the Andersen Health Behavioral Model to better understand the importance of the
relationship between the patient and clinician in helping to facilitate ARV treatment adherence
for PLWH. They found that PLWH’s trust in their medical provider and medical treatment were
key factors that influenced their ARV treatment adherence. Trust was further influenced by a
patient’s predisposing factors, or personal and social history with medical treatment, as well as
factors that enabled their access to treatment and their perceived need for treatment. While the
researchers acknowledged the need for more research in this area, they suggested that PLWH
who trusted their medical provider were more likely to adhere to their ARV treatment.
While Social Cognitive Theory and the Andersen Health Behavioral Model help explain
the importance of self-efficacy and trust in medical provider in relation to PLWH’s ARV
treatment adherence, these theories do not appear to adequately explain how low-income PLWH
of color overcome the multitude of barriers to medication adherence described in the empirical
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literature to build self-efficacy and trust in their medical care despite the barriers. Therefore, a
review of the theoretical literature on medication treatment adherence in general (not specific to
ARV treatment adherence) was conducted to shed light on the field’s theoretical understanding
of medication adherence for any chronic condition. It is interesting to note that among adults
with other chronic illnesses such as diabetes and hypertension, approximately a third to a half do
not take their medication as prescribed (Kini and Ho, 2018), suggesting that poor medication
adherence is not unique to PLWH.
A meta-analysis of 124 evaluations of theory-informed interventions to improve
medication treatment adherence was conducted to understand which interventions were most
effective. The most common chronic conditions included in the studies were HIV, hypertension,
cardiac disease, diabetes and asthma (Conn et al, 2016). Eleven different theories were used as
frameworks for the various interventions to improve medication treatment adherence. Of those,
the intervention, Motivational Interviewing, which is based on Social Cognitive Theory, was the
most common theoretically informed intervention applied. However, the theories that had the
largest effect size on behavior were the Health Belief Model (d=0.477) and Adult Learning
Theory (d=0.443) (Conn et al., 2016). The premise of the Health Belief Model is that people’s
health-related behavior is a cost-benefit analysis comprised of their perception regarding their
susceptibility to a disease and the severity of the disease (the cost) and the benefits and barriers
associated with changing behavior to avoid disease or treat an illness. Cues to action such as
feeling symptoms of disease or advice from others to change behavior, combined with one’s selfefficacy regarding their perceived ability to change their behavior are also factors explained by
the Health Belief Model (LaMorte, 2019). Adult Learning Theory recognizes that adults learn
differently from children. According to the theory, adults prefer to learn from experience, using a
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hands-on approach that solves actual problems and has immediate relevance (Meij, n.d.). Thus
applying this understanding about how adults learn when educating them to adhere to their
medication can help enhance treatment adherence. However, the researchers of the meta-analysis
concluded that the treatment adherence interventions based on these theories produced
significant but only modest impact on medication adherence outcomes (Conn et al, 2016).
Absent from these studies is the ecological, or real world, context for understanding treatment
adherence, which if better understood, could help fill the gap in understanding about the factors
that contribute to people’s ability to adhere to their medication, specifically people who face
various a multitude of barriers to adherence.
Kini and Ho (2018) reviewed 49 studies that evaluated interventions to improve
medication adherence for chronic disease and concluded that the subject is complex due to the
fact that it involves competing factors related to the patient, clinician and healthcare system. As
noted by the previous theories discussed, the patient factors are the personal factors that
predispose the patient to healthcare, such as their knowledge, attitudes and beliefs about their
medical condition and need for treatment as well as their self-efficacy to take their medication as
prescribed. However, medication adherence is also influenced by clinician factors such as the
medical providers’ ability to diagnosis the disease, prescribe the right medication, communicate
the need for medication, and coordinate the care with the patients’ other providers. Finally, the
health system factors include the environmental and structural barriers noted above related to
access to healthcare, medication, and health insurance.
In an editorial of Psychology & Health, Molley and O’Caroll (2017) further suggested
that while the behavior associated with medication adherence is similar to other health-related
behaviors that require daily maintenance, such as smoking cessation, exercise and healthy eating,
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medication adherence behavior differs from these other behaviors in three key ways. The first
key area unique to medication treatment adherence is that unlike other health behavior change
efforts, medication adherence is reliant on a prescription written by a healthcare provider. The
second one is that receipt of the prescription usually does not coincide with prolonged social
interactions with a provider, or trained personnel, to help with making the sustained behavior
change, such as with a smoking cessation program or exercise class. Finally, the third key area is
that the medication treatment for a chronic condition aims to prevent or minimize the worsening
of a condition and therefore does not coincide with the immediate relief of symptoms or
immediate improvement that often motivates people to continue the new behavior (Molley &
O’Carroll, 2017). As a result, the application of these established behavior change theories, such
as the Health Belief Model, to medication treatment adherence of a chronic condition may be
inappropriate (or a poor fit).
Therefore, the review of the theoretical literature on medication adherence in general
revealed that there is currently no overarching theory that adequately explains why people adhere
to their medication for any chronic condition, HIV or otherwise. In fact, the theoretical literature
on medication treatment adherence of a chronic condition suggests that the existing healthrelated behavior change theories do not adequately or comprehensively explain the complexity of
the topic. With specific regard to low-income PLWH of color, there is a gap in the literature and
understanding in the field as to how and why some members of this vulnerable population are
able to overcome the barriers to achieve viral suppression. This qualitative study based on
Constructivist Grounded Theory aimed to fill this gap in understanding about treatment
adherence by employing inductive, qualitative research techniques. The data was grounded in the
lived experience of the low-income PLWH of color who have successfully overcome the barriers
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to ARV treatment adherence and achieved viral suppression. The purpose of the study, therefore,
was to generate theory that explains how and why they were able to do this. The following
chapter explains the methodology employed to conduct this study.

Running Head: ARV Treatment Adherence Model

28

Chapter 3. Methodology
The purpose of this study is to explore the process by which a population of virally
suppressed, low-income PLWH of color from NYC became virally suppressed through ARV
treatment adherence. Once again, the research questions explored by the study are:
1) What was the process by which low-income PLWH of color from NYC became virally
suppressed through ARV treatment adherence?
2) What motivated them to become virally suppressed?
3) What barriers did they perceive to ARV treatment adherence?
4) How did they overcome these barriers?
Research Approach
Rationale for qualitative methodology. Qualitative research was the proposed research
methodology for this study. Qualitative Research aims to uncover a deep understanding of a
particular concept, grounded in the real world experience of those impacted by a phenomenon
(Bloomberg & Volpe, 2019). There are several reasons for doing qualitative research. These
include the exploration of an emerging, relatively unknown topic; the pursuit of a topic that is
sensitive and requires emotional depth; to uncover the complexity of a topic, or a detailed
understanding of an issue that can only be obtained by talking directly with those impacted by it
and allowing them to tell their story; and in pursuit of social justice by giving voice to those most
oppressed by society (Creswell & Poth, 2018; Padgett, 1998). With regard to ARV treatment
adherence, the review of the theoretical and empirical literature revealed that the reasons why
low-income PLWH of color take their medication despite facing barriers to treatment is complex
and relatively unknown, and therefore an emerging topic. Furthermore, due to the nature of HIV,
specifically with regard to its mode of transmission (sexual contact or injection drug use), and
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the fact that it disproportionately impacts highly vulnerable and historically discriminated against
groups in our society (e.g., SMM, people of color, and substance users), the associated stigma
attached to the disease makes it a sensitive and emotional topic of inquiry. Finally, from a social
justice perspective, there is a particular interest in obtaining the lived experience of these
oppressed members of society, to not only develop a theory that is relevant to their experience
but also to give voice to something they are doing right and empower them to share their
experience and strategies with others. For these reasons, qualitative research was identified as the
appropriate research methodology for this study.
Constructivist Grounded Theory. Within the field of qualitative research, there are
several approaches or strategies for achieving the goals cited above, each one drawing from a
discipline within the social science field, such as anthropology, sociology, and psychology
(Creswall & Poth, 2018). Constructivist Grounded Theory is the qualitative research approach
selected for this study. Grounded Theory grew out of sociology and offers a structure and
guidance to generate theory that is grounded in issues that are important to the lives of everyday
people (Mills, Bonner & Francis, 2006). Constructivist Grounded Theory is based on Grounded
Theory but incorporates concepts from Constructivism, or the interrelationship between the
researcher and participant who co-construct meaning, or the interpretation of the data, that is
grounded in the participants’ lived experience (Mills, et al., 2006). Constructivist Grounded
Theory was selected because the purpose of the study was to generate theory, or understanding,
about the process by which a group of low-income PLWH of color overcame barriers to ARV
treatment adherence to achieve and maintain viral suppression. The goal was to construct their
understanding of this process through inductive inquiry and the application of rigorous data
analysis that recognizes and incorporates the researcher’s role, as an instrument in the analysis.
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History and Development of Grounded Theory. Grounded Theory was first introduced
in the late 1960s by Glaser and Strauss who explained in their groundbreaking text Discovery of
Grounded Theory that in contrast to the positivist (deductive) approach that tests theories, a
qualitative (inductive) approach is a better fit for theory development due to its inductive nature.
Rather than being based on the researcher’s preconceived notions about the concept, it is
grounded in the lived experience of the participants (Bloomberg & Volpe, 2019; Mills, et al.,
2006; Patton, 2002; Charmaz, 2014; Strauss, 1987). It is further based on the notion of human
agency (human beings as active members in their lives and in their worlds) that informs how
humans act, their engagement in the process, and the meaning they attribute to their actions
(Charmaz, 2014; Strauss, 1987). Thus, the theory that emerges from the data is practical and
relevant to their lives.
The methodology for conducting qualitative data analysis using a Grounded Theory
approach involves a standardized and rigorous process, including a multi-step coding process
from open or initial coding (coding of the raw data focused on participants’ actions) to focused
and axial coding that reassembles the data into an emerging theory. This framework moves the
analysis beyond description and into the development of an explanatory theoretical framework
grounded in the experiences of the research participants and the meaning they attribute to that
experience (Charmaz,, 2014, Bloomberg & Volpe, 2019; Patton, 2002; Strauss, 1987; Padgett,
1998).
Over the course of the past 50 years since Glaser and Strauss first developed and wrote
about Grounded Theory methodology, they continued exploring its application, disagreed over
aspects of its underlying philosophy, and influenced numerous future researchers to further
expand on their teaching and guidance. Researchers have been critical of Grounded Theory for
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being too rigorous and mechanical, as well as disingenuous to some core features of inductive,
qualitative research, such as being grounded in the lived experience of the participants and not
influenced by the researcher’s preconceived notions or understanding from literature (Bloomberg
& Volpe, 2019). Mills et al. (2006) describe the evolution of Grounded Theory as a
methodological spiral, from its initial scripted coding structure that did not incorporate the
researcher as instrument in the analysis, to its current form known as Constructivist Grounded
Theory.
Charmaz, a student of Strauss, developed Constructivist Grounded Theory during the late
1990s, and is one of the leading researchers in the field to take Grounded Theory to this next
level (Bloomberg & Volpe, 2019; Mills et al., 2006; Charmaz, 2000, Charmaz, 2014). As noted
above, Constructivist Grounded Theory incorporates the guidance of Grounded Theory with the
teachings of Constructivism. It more explicitly recognizes the role of the researcher in the data
collection and analysis process, the researcher as not neutral or objective but rather as an
instrument engaged in the analysis (Charmaz, 2014). The researcher, along with the participants
of the study, co-construct the theory that is grounded in and emerges from the data to explain the
phenomenon in question. It further offers a more flexible approach to the data collection and
analysis process that allows the researcher to go where the data takes her (Charmaz, 2014).
Therefore, in order to ensure that the theory that emerged from this study on ARV treatment
adherence for a population of low-income PLWH of color was both grounded in their lived
experience with the phenomenon and transparent about the researcher’s role in the analysis,
Constructivist Grounded Theory was identified as the most appropriate approach to apply to this
study.
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Study Design
Based on the written guidance on Constructivist Grounded Theory, the study design was
systematic but flexible based on an iterative process of data collection and analysis that occurred
simultaneously and acknowledged the researcher’s subjective role in all aspects of the process
(Charmaz, 2014). As a result, the themes and patterns generated from the findings from this
study formulated a theory about the process of ARV treatment adherence for low income PLWH
of color.
Study Sites
Participants were recruited from 3 nonprofit, community-based organizations in New
York City with long histories of serving low-income PLWH of color (names of the agencies
withheld to protect the identities of the participants). These agencies were formed during the
1980s under the auspices of the New York State Department of Health, AIDS Institute’s
Community-based Initiative. This initiative provided funding to grassroots organizations that
were formed by and with a specific mission to serve members of the communities hardest hit by
the AIDS epidemic. Thirty years later, these organizations still exist and are still serving many of
these same populations. While their funding and services have diversified, as they adapted to the
changing needs of the epidemic, specifically with regard to the discovery of ARV treatment
which transformed the virus from a fatal disease to a chronic condition, they have managed to
stay true to their initial missions of serving those members of society who were most vulnerable
and most impacted by the virus. In line with the Federal, State and City’s goal of ending the HIV
epidemic, these organizations work hard to increase the viral load suppression rates of their
clients and thus have expressed interest in and support for the results of this study. All gave
permission to this researcher to recruit participants at their sites.
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It should be noted that this researcher is an employee of one of these agencies. However,
she conducted this research for her Ph.D., and it was therefore not related to her work at the
agency. During the screening and informed consent process, participants recruited from the
agency where she worked were informed about the researcher’s affiliation with the agency. It
was explained that although she works for the agency, she was conducting the study for her own
personal reasons. They were informed, as were all of the participants, that their participation was
voluntary, confidential, and that no one else besides the researcher would be aware of their
participation or what they said. All data was encrypted and stored in a location outside of the
agencies and no identifying information about the participants was included in this report. How
the researcher’s affiliation with the agency and years of experience doing HIV work was
addressed during data collection and data analysis is further discussed at the end of this chapter,
in the section on Trustworthiness and Credibility.
IRB Approval
An IRB application was submitted to the City University of New York (CUNY)
University Integrated Institutional Review Board (IRB) and approved on 7/6/2020 (Appendix A).
The application included the letters of support from the study sites as well as the procedures for
participant recruitment, informed consent, and data collection detailed below.
Sampling Framework
A nonprobability, purposive and snowball sampling strategy was employed for this
research study. To recruit the initial participants, fliers were posted at the cooperating nonprofit
community-based organizations, in various locations including on each agency’s public bulletin
boards, newsletters, social media sites and websites (Appendix B). The fliers detailed the
eligibility criteria for the study as follows:
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Adults (at least 26 yrs. old or older)



People of color (Black/African American and/or Hispanic/Latinx)



PLWH who maintained viral suppression for the past year (confirmed by medical
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documentation)
The rationale for focusing the study on adults 26 years of age or older was to focus on the
struggles of an adult population as opposed to young adults or teenagers. Adults are more likely
to have struggled with the barriers to ARV treatment adherence, such as stigma, poverty,
substance use and mental illness, for longer periods of time than young adults or teenagers, and
thus have a different, more complex life history with ARV treatment adherence. In addition,
depending on when they were first diagnosed, it is possible that the older adults were first
prescribed the medicine in the late 1990s or early 2000s, when there were many more side
effects and complicated regimens associated with the treatment, and thus have a different
relationship to the medicine than their younger counterparts. Finally, it is possible that young
adults or teenagers could have been born with the virus as opposed to having contracted it
through some risk behavior, and thus may have a different emotional attachment to the disease
and its treatment. Therefore, in order to ensure that the participants had a similar life experience
in relation to HIV and the barriers to treatment, the researcher decided to exclude young adults
and teenagers from the study.
The rationale for focusing on people of color, specifically African Americans and Latinx,
was because of the disproportionate impact of the virus on these racial and ethnic groups as well
as the disparity in rates of viral suppression, compared to Whites. The purpose of this study was
to specifically unpack how these communities of color overcame barriers to ARV treatment
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adherence to become virally suppressed, taking their unique histories of racism and
discrimination into account.
The eligibility criteria that required participants to provide medical documentation
indicating that they had been virally suppressed for at least one year was based on guidelines put
forth by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents which indicate
that PLWH need at least 2 consecutive viral load tests conducted 6 months apart to demonstrate
sustained viral load suppression (DHHS, 2019).
In addition to the eligibility criteria, the flier described the purpose of the study,
expectations for participation (1-2 face-to-face intensive interviews), and the incentive provided
in exchange for their participation (a $20 Gift Card). Also noted on the flier was the researcher’s
contact information so that interested participants could contact the researcher directly to
schedule the interview.
Additional eligibility criteria not included in the flier but assessed during the screening
process included the participants’ low-income status and ability to communicate in English.
During the telephone screening, participants were asked to self-report if they were on Medicaid
or ADAP in order to demonstrate that they were low-income and thus, more likely to have
experienced financial and other structural barriers related to poverty, such as homelessness, food
insecurity, transportation barriers, etc. Finally, participants needed to be able to communicate
comfortably in English due to the researcher’s limited ability to communicate in Spanish.
Unfortunately, this meant that the experience of PLWH who do not speak comfortably in English
was not included in this study and therefore the findings may not reflect their experience with
ARV treatment adherence. Comfortability speaking English was determined during the screening
process. If the participants appeared able to comprehend the researcher’s screening questions and
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were able to communicate their responses in English, they were considered eligible for this
study.
Participant Recruitment. Recruitment for this study was initiated during the summer of
2020 and continued through the Spring of 2021. In other words, recruitment and the subsequent
interviews took place during the COVID-19 pandemic when it was considered not safe to
conduct the interviews in-person. While it was not part of the original intent of the project, at the
time of the screening, participants needed to agree to be interviewed over Zoom, which further
meant that they had to have the required technology, such as a computer, tablet, or smart phone,
to participate in the study, and the skillset required to use Zoom.
Finally, with regard to recruitment, and in keeping with the guidelines of Grounded
Theory, over the course of the interview and data analysis process, the researcher employed
theoretical sampling to seek and collect relevant data to fill in gaps in understanding that arose as
the data was transcribed, coded and the emerging theory revealed (Charmaz, 2014; Strauss,
1987). For example, about halfway through the interview process, it became apparent that no
women were responding to the fliers posted at each agency. Therefore, the researcher reached
out to her contacts at the agencies to ask if they could post the fliers at specific sites where
female clients frequented. The strategy worked, because at least one female participant
responded. And through her, and snowball sampling, other female participants reached out based
on a referral from their friend who saw the flier.
Participant recruitment continued until the researcher reached saturation. In other words,
this was the point in the data collection process at which there were no new ideas emerging from
the participants’ interviews but rather different variations on similar themes and concepts with
respect to their experience with ARV treatment adherence.
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Telephone Screening. Interested participants were screened for eligibility for the study
by the researcher over the phone prior to scheduling the interview. During that phone call, the
researcher reviewed the purpose of the study and eligibility criteria. If participants self-reported
that they met the eligibility criteria for the study, including being virally suppressed for at least
one year, and were interested in participating in the study, the researcher explained that due to
COVID and the need to be socially distant, the interview would need to take place over Zoom.
She asked the participants if they had the necessary equipment to participate in a Zoom meeting,
such as a computer, tablet, or Smart phone. If they said yes and consented to conducting the
interview over Zoom, the researcher scheduled the interview at a mutually agreed upon time and
followed the conversation with an email that included the Zoom link. To offer added security and
protection to the participants, the researcher used a secure Zoom account she was provided by
the City University of New York (CUNY).
It was also explained during the phone screening and repeated in the follow up email that
in order for the interview to proceed, by the time of the interview, the participants needed to
provide a copy of their medical documentation that confirmed their sustained viral load
suppression status for at least the past year. They were told that if it was determined that they
were not eligible for the study based on their medical documentation, they would not be eligible
for the Gift Card incentive for the study. All participants who completed the interview either
emailed a copy of their medical documentation to the researcher prior to the interview or held up
a copy of the documentation to the camera during the Zoom meeting so that the researcher could
view it and confirm their eligibility.
Informed Consent. Finally, the researcher explained during the phone screening and
follow up email that the participants would need to sign a copy of the Informed Consent prior to

Running Head: ARV Treatment Adherence Model

38

proceeding with the interview. The Informed Consent detailed the purpose of the study,
procedures for participation, including that participation was voluntary and confidential, and the
risks and benefits to the participants. It was also noted that with consent from the participant, the
interview would be recorded (via Zoom) and transcribed for the purposes of data analysis. The
transcriptions excluded identifying information and were encrypted to protect the participants’
confidentiality. The Informed Consent was attached to the follow up email and participants were
asked to review it prior to the interview. They were told that if they had any questions, they
could ask them at the time of the interview. If not, they were asked to print the form, if possible,
sign it, and either scan it back to the researcher or take a picture of the page with their signature
and email or text the picture to the researcher. Most of the participants had no problem
completing this task. However, a few sought help from a Case Manager or other staff member at
the community-based organization of which they were affiliated.
The Interview Guide
A semi-structured, open-ended interview guide was used to guide the intensive interviews
with study participants (Appendix C). The interview guide was informed by the sensitizing
concepts highlighted by the theoretical and empirical literature which identified the known
facilitators and barriers to ARV treatment adherence. The interview questions covered the
process the participants followed to adhere to their medication, what motivated them to take their
medication as prescribed, the barriers they faced in the process, and if they did face barriers, how
they overcame them. The questions further explored the participants’ self-efficacy related to
ARV treatment adherence, their personal beliefs about the medication, and their experience with
their medical providers and the healthcare system. Finally, with regard to the barriers cited in the
literature, the participants’ history with poverty, housing instability, mental illness and substance
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use was explored in relation to their experience with ARV treatment adherence as well as their
experience with HIV stigma, racism and other forms of discrimination that may have impeded
their ability to take their medication as prescribed.
While the sensitizing concepts informed the interview guide and interviews, in keeping
with the Constructivist Grounded Theory guidelines, specifically with regard to role of the
literature review to not restrict the data analysis process, the researcher was open to go where the
data took her, and flexible with the process. The interviews followed the participants’ leads about
their experience with ARV treatment adherence and the barriers that they experienced and
needed to overcome.
Data Collection and Analysis
Intensive Interviewing. After the participants were screened and deemed eligible for the
study, they met with the researcher over Zoom for the intensive interview which lasted for about
1-2 hours. According to Charmaz (2014), intensive interviewing focuses the topic while allowing
participants the space and time to provide their views and insights that inform the emerging
theory. In recognition of the researcher as an instrument in the process, throughout the data
collection process, the researcher reflected back what she heard from the participants as the data
was collected, for clarification purposes and verification that it was being received as the
participant intended. This included attempting to maintain a consciousness regarding the
researcher’s preconceived notions about the subject and the participants, as well as how the
participants perceived her, to factor in how these issues influenced her interpretation of their
responses and use that to clarify any misinterpretations. In other words, together, the participants
and the researcher co-constructed the theory based on their shared and reflected understanding of
the meaning the data.
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Memo Writing. While collecting the data through intensive interviewing, the researcher
wrote memos detailing her observations and initial thoughts about the data that were used to
inform her initial data codes (Charmaz, 2014; Charmaz, 2006; Padgett, 1998; Strauss, 1987).
Thus, the memos were part of the data collection and analysis process. Padgett (1998) explains
that coding decisions should be discussed in the memos as a means of tracking the researcher’s
thought patterns and justifications for the decisions made throughout the analysis.
Coding. To quote Charmaz (2006): “Grounded theory coding generates the bones of
(the) analysis” (p. 45). Codes emerge in the process of interacting with the data, assigning
meaning to the data, and asking questions of the data (Charmaz, 2006). According to Strauss
(1987), it is the Grounded Theory coding process that move the data analysis from description to
higher level abstraction and theory development. The initial codes, called open-codes or in vivo
codes, are grounded in the data and the words of the participants. The process is to go line-byline and label each segment as an action, using the actual language of the participants (Charmaz,
2014; Padgett, 1998; Strauss, 1987).
For this study, this process was initially done on paper. The researcher read through each
transcribed interview and penciled a tentative in vivo code in the right margin to label the main
concept revealed by the data. The tentative codes were simultaneously tracked in a code book,
which was an excel spreadsheet that listed the code and the interview number and page number
that coincided with that code, so that the researcher could return to that section of the interview
as more data was collected and revise the code as needed, or as deeper thoughts about the codes
emerged. Thus, by staying as close to the data as possible and by using the language of the
participants, the open, in vivo coding process minimized premature interpretation on the part of
the researcher. The purpose at this stage of the coding and analysis process was to label the
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concepts that described the complexity of the ARV treatment adherence phenomenon and to
resist making conceptual leaps and developing theory before completing the analytical work.
For example, as part of the process of trying to understand the barriers to treatment
adherence for the participants, the researcher coded any comment about a barrier as “barrier to
adherence”. She then reviewed all the comments coded as “barrier to adherence” and categorized
them into type of barrier. Several participants talked about how they felt “overwhelmed” by the
idea of having to take medicine for the rest of their life. These comments were then coded as
“Barrier to adherence – rest of life/overwhelming”. Similarly, the researcher was interested in
how and why the participants were able to overcome the barriers and take their medication.
Therefore, any comment that appeared to refer to a strategy for overcoming a barrier was coded
“Adherence Strategy” and then fine-tuned by type of strategy, such as “Adherence Strategy –
Daily Routine”. Finally, a comment that reflected a participant’s motivation to adhere to their
medication was coded at first as “Motivation” and then later by type of motivation, such as
“Motivation – To Live”.
After all the interviews were conducted and the open codes refined and given subcategories, the researcher proceeded to the second phase of the coding process called focused
coding. The focused coding process reviews the memos and initial codes generated from the data
and looks for meaning and comparisons between them (Charmaz, 2014). Strauss (1987) called
this process a process of fracturing the data. One of the goals of focused coding is to verify the
strength and accuracy of the initial codes, to help determine which of the many possible paths to
follow to the third stage of the coding process, the axial coding process (Charmaz, 2014,
Bloomberg and Volpe, 2019). Charmaz (2006) further explained that focused coding was not a
linear process but rather a process of allowing the theoretical insights that were grounded in the
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data to emerge, which then require the researcher to go back and re-review the data and possibly
revise some of the initial codes. Thus, as noted above, the process is flexible and not linear, as
the researcher remains open to go where the data takes her.
For this study, the focused coding process was completed using a software called
Quirkos. Each interview was uploaded to the software and following the open codes written on
the paper copies of the interviews (and refined over the course of the interviewing process), code
files were created in Quirkos. The section of each interview that was labeled by a specific code
was then highlighted in the software and pasted into the file for the corresponding code. In other
words, by the end of the analytical process, the researcher had a multitude of files that contained
all the data from the various interviews that addressed a particular code, or concept important to
unpacking the process of ARV treatment adherence. Appendix D and E present examples of 2 of
these files, for the codes “Barrier to adherence – rest of life/overwhelming” and “Motivation –
To Live”.
Finally, the process of axial coding looks for categories and dimensions in the data, in
order to sort, synthesize, and reorganize the data to provide coherence to the emerging analysis
(Charmaz, 2014, Charmaz, 2006). Once reorganized in Quirkos, the data was reviewed and
analyzed again to unpack the emerging theory that helped explain the process of ARV treatment
adherence for the population of low-income PLWH of color engaged in this study. The following
chapter presents the findings from this analytical process of reassembling the data after it was
fractured during the focused coding process. The themes and patterns that emerged from the data
formulated a theory that complements and enhances the current theories about ARV treatment
adherence and fills in the gaps in understanding about the process. This more comprehensive
theory, which is presented in the final chapter, the Discussion Chapter, therefore reflects the
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complexity of the topic of medication adherence for low-income PLWH of color and is grounded
in the real world, based on the participants’ lived experience.
Trustworthiness and Credibility
Trustworthiness and credibility of the data refers to the internal validity of the study,
whether the findings accurately reflect the experience of the participants in the study (Bloomberg
& Volpe, 2019). For this study on ARV treatment adherence, trustworthiness and credibility of
the data was addressed in several ways. First, with regard to data collection, the researcher used
reflexivity to maintain an awareness of her positionality and how she was being perceived by the
participants. The goal of the research was to uncover the participants’ truth, their lived
experience with ARV treatment adherence. Therefore, throughout the data collection process, the
researcher maintained an awareness of how she was being perceived by the participants and
reassured them that they were the experts on this subject and that her role was to learn from them
about their experience with ARV treatment. In addition, during the interviews, the researcher
reflected back to the participants what she was hearing them say. This process provided the
participants with opportunities to correct or clarify misunderstandings or expand on any insight,
while strengthening their trust in the researcher that she was listening carefully to them, so that
they felt comfortable disclosing their truth.
The researcher was also conscious about her preconceived notions, or possible bias, about
ARV treatment adherence, developed over the course of her 20+ years of experience doing HIV
work with underserved populations. For example, having worked in the field for so many years,
the researcher had witnessed firsthand some of the barriers to accessing quality healthcare for
low-income PLWH of color discussed in the literature. However, the purpose of this study was
to uncover barriers these participants experienced with regard to ARV treatment adherence and
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how they overcame them to become virally suppressed. She therefore made a conscious effort to
seek out negative cases, or in this case, examples that contradicted her expectations, to ensure
that the study was capturing the full story with regard to ARV treatment adherence.
Trustworthiness and credibility were further maintained during the data analysis phase of
the process, through the use of a code book and audit trail, which was maintained and developed
as the data was collected. The researcher used her memos about her initial thoughts and
observations after each interview to inform her decisions about the codes which were listed in
her code book and revised and tweaked as more data was collected. The audit trail and code
book, therefore, provided a check and balance in her effort to verify the authenticity of the codes
as labels depicting the lived experience of the participants. Finally, the researcher used peer
review (members of her dissertation committee and a colleague), to review early drafts of her
findings compiled during the axial coding stage of the process. These early drafts detailed her
initial thoughts about the structure for the analysis, after the data was dissected and reassembled,
that informed the emerging theory about how low-income PLWH of color overcame barriers to
ARV treatment adherence to achieve viral suppression. Her advisors and colleague offered
insight regarding the accuracy of the codes as reflections of the data presented, thoughts about
their deeper, contextualized meaning, and the analysis. This helped the researcher verify that the
analysis reflected the lived experience of the participants and not her preconceived notions and
biases about the phenomenon.
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Chapter 4: Research Findings
The Participants
Fourteen virally suppressed, low-income, people living with HIV (PLWH) of color
participated in this qualitative study based on Constructivist Grounded Theory aimed at
exploring the process of ARV treatment adherence. This chapter presents the findings from the
open-ended, in-depth interviews with these participants. To protect their identities, each
participant was assigned a pseudonym and any identifying information about them was omitted.
Twelve of the 14 participants were recruited from the 3 study sites referred to in Chapter 3. The
other two were recruited via snowball sampling: they were referred to the researcher by one of
the other participants. The majority (10) identified as male while the other four participants
identified as female. None identified as transgender. Eight of the 14 identified as Black/African
American while the other six (all males) identified as Latino. A few (3) were foreign born, from
the Caribbean or Central America. Those who were from the United States were mostly from the
New York area, although two mentioned being from the South originally. They ranged in age
from 28 to 66 years old. Because it did not seem relevant to the research questions, the
participants were not asked directly about their sexual orientation, but several discussed their
sexuality in the context of their HIV status and life experience. While the women described past
relationships with males and therefore described heterosexual relationships; their sexual identity
is unknown. In contrast, several of the men described themselves as either gay or bisexual, which
appeared to be an important aspect of their identity.
Per the eligibility criteria to participate in the study, all of the participants were HIV
positive and virally suppressed for at least the previous year. This was confirmed at the time of
the interview based on medical lab work they provided indicating a sustained viral suppression
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status from within that time period. The length of time each participant had lived with HIV
varied significantly, from less than five years to over 30 years, though most had been HIV
positive for at least 10 years. Some reported being virally suppressed from the time of their
diagnosis, while most, especially those who were diagnosed during the 1980s or early ‘90s, said
their viral loads fluctuated over time.
In addition to HIV, most of the participants of this study had other chronic medical
conditions, such as diabetes, high blood pressure, cancer, mental illness, as well as some rare
medical conditions they had since childhood. Therefore, their conversations about the barriers to
medication adherence and their strategies for overcoming them reflected on all of their
diagnoses. Because the interviews took place during the COVID-19 global pandemic, their
answers were also influenced by their thoughts and fears about COVID-19 and the COVID-19
vaccine.
The findings from this study are organized by the sensitizing factors identified in the
empirical and theoretical literature as key factors that explain ARV treatment adherence for the
participants of this study. The first sub-section describes the structural barriers the participants
experienced in healthcare, including their experience with HIV stigma, health insurance, medical
provider turnover, and lack of time with medical provider. The next sub-section explores the
participants’ positive experience with healthcare and how this positive experience helped build
their trust in medical provider and the healthcare industry that helped them overcome the
structural barriers to ARV treatment adherence. This section is followed by a sub-section
describing the behavioral and psychosocial barriers that impacted the participants’ ARV
treatment adherence, such as substance use, mental illness, and homelessness, and how they
overcame these barriers.
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The last few sections of this chapter explore the personal factors that influenced the
participants’ ARV treatment adherence, such as their personal knowledge, attitudes and beliefs
about the medication and their self-efficacy, or perceived ability, to take the medication as
prescribed. Self-efficacy is explored in the context of the participants’ expressed need to accept
their chronic condition and subsequent need to take medication to survive, become empowered
healthcare consumers, and finally develop concrete strategies that helped them overcome the
challenges to taking medication on a daily basis. The chapter concludes with a sub-section on
motivation, or the factors that motivated the participants to take their ARV medication.
Motivation is a factor that appears missing, or is not well understood, from the previously
discussed theories and is therefore a factor that helps fill the gap in understanding about the
phenomenon known as ARV treatment adherence for low-income PLWH of color.
Structural Barriers to ARV Treatment Adherence
As noted in the literature, structural barriers created by the healthcare system can
interfere with PLWH’s ability to access medical care and treatment, adhere to their ARV
medication, and become virally suppressed. Every participant of this study described a time in
their life when their ARV treatment adherence was compromised due to an external factor
related to the healthcare system that was outside of their control. Such barriers included feeling
stigmatized for having HIV or discriminated against in general, by medical providers and the
medical establishment, that lead to feelings of low self-worth, misinformation that put them at
risk of other diseases, and disengagement with healthcare. Other barriers included changes in
their health insurance and health insurance policies, medical provider turnover, and medical
providers’ lack of time to spend with them, that impacted their continuity of care and sense of
trust in the system.
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HIV stigma and other forms of discrimination
HIV stigma was a common theme discussed by the participants. With regard to their HIV
medical care, every participant talked about their struggle to find the right doctor, the right
facility, that made them feel safe, not judged for who they were, and with whom they would
entrust their care. They shared painful stories of discrimination and stigma on the part of the
medical establishment that left them feeling ashamed and worthless; experiences that impacted
their health outcomes and delayed their ability to achieve and maintain viral suppression. Melissa
described a nurse who put on gloves to take her blood pressure. She asked why that was
necessary because there was no blood involved in the exchange but was told it was protocol.
However, she said she observed that the nurse did not use gloves with other patients. Julio
mentioned how he hated going to visit his doctor at his first clinic because at that facility all HIV
patients were seen on the 3rd floor: “I didn’t like how the 3rd floor was only for HIV positive
people. Everyone knew that. If you go to the 3rd floor, you know my HIV status is already in
jeopardy of being disclosed without my permission because this one floor is only dedicated to
HIV positive people…”
Several participants talked about their experience when they were first diagnosed with
HIV, especially if it was early in the pandemic when there was little known about the virus
and/or if they were living in a community outside of NYC that had much less experience treating
people who had it. Nate found out he was HIV positive when he was in the army. He explained
that because he was not out as bisexual to himself much less anyone else at that time, and the
army doctors didn’t ask the right questions, he was given the wrong information about how to
protect himself and protect others from getting infected. The doctors assumed he was straight
and therefore talked about his sexual risk behavior in the context of heterosexual contact. As a
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result, he ignored their advice because he didn’t think it applied to him since he wasn’t having
heterosexual sex: “The doctors were very judgmental… They withheld information that
would’ve been very helpful to me. … I’m like, that doesn’t apply to me …. (since) I hadn’t slept
with a female in a while.” Similarly, Roberto talked about a time when he was forced to leave his
doctor’s practice because his health insurance had changed and he was assigned a new provider.
At the time of the change, he was stable and virally suppressed. However, his initial experience
with the new provider was so negative that he stopped going to the doctor and stopped taking his
medication.
Even though it was a great facility, great location, I got the worst service. Don’t get me
wrong. The team was great. The provider was horrible. She didn’t wanna sit next to me.
The way she spoke to me—she knew everything as if it was a SAT test, meaning
terminology, academic-wise. But she had no experience—no lived experience, no
patients outside of on paper. … (She) wasn’t giving me accurate information because she
didn’t make me feel like my time was valued…
Health Insurance
Barriers associated with health insurance and general bureaucracy of the healthcare
system interfered with several participants’ continuity of care and treatment, as well as added to
their frustration with the system. As noted above, when Roberto was forced to change his
medical provider due to a change in his health insurance policy that no longer covered the
physician he was seeing, and because the new provider treated him so poorly, he stopped going
to the doctor, stopped taking his medications, relapsed on substances, and ended up in the
hospital with pneumonia. He talked about how he had to advocate to get his health insurance to
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cover his preferred provider again. Eventually, his health insurance agreed to cover his original
provider, and he was able to get back on track with his medical care and sobriety.
I was forced, because of guidelines—and I understand that’s the world we live in, and
sometimes life throws you off, and there’s rules and protocols in place, but again,
because of the inconvenience of a simple thing as guidelines and because of insurance, I
had to switch providers, and my health dramatically decreased. For maybe three or four
months, I became detectable … I had to fight with (my health insurance) to fix (my
provider’s) profile, because she wasn’t a level three, which is a HIV doctor specialist, on
the (health) insurance’s profile… Until they fixed her profile, I was denied service at (that
clinic) to see (my preferred provider). …Thank God I’m now a client of hers again.
Fernando had a similar experience which he took personally:
Yeah, and it was kinda like a—I (felt) like I failed. I was working so hard, keeping my
viral load down, limiting partners, practicing safe sex, keeping up with my treatment
adherence. Then when something as small as you running out of medicine or your
insurance not paying for the medicine or … a doctor visit, being the only reason you’re
no longer suppressed, oh, that hurt like a personal—like I failed somehow.
Medical Provider Turnover
While in some cases, the participants changed their medical providers because of their
personal choice, in their search for a provider they liked and trusted, most experienced a change
in medical provider, or multiple changes, due medical provider turnover. Each change in medical
provider led to a delay or disruption in their medical care that impacted their health outcomes
and ability to achieve or maintain viral suppression. High medical provider turnover impacts the
trusting relationship many of the participants said they valued in their relationships with their
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doctors. As noted in the literature, trust in medical provider and healthcare in general is key to
trusting the medication and believing that it is in their best interest to take it (Petrovic and Blank,
2015). Furthermore, specific to the African American community, although relevant to other
minority groups, lack of trust in the healthcare industry as a result of historical abuses,
discrimination and systemic racism, has been shown in the literature to be a known barrier to
healthcare for people of color (Gaston & Alleyne-Green, 2013; Mattocks et al., 2017). Evelyn
described how she felt when her favorite doctor left her practice: “She was (a) great doctor….
When she wound up leaving, I was crying like a baby.”
One common complaint made by the participants was that they would need to repeat their
life history each time they had a new provider: “Every three months or three to six months when
I would go in for a doctor's visit, they would have a new doctor for me, and I had to tell my
whole life story all over again before they would even … see me”, said Fred. On the other hand,
while not happy about it, Ian expressed complacency regarding medical provider turnover, and
appreciation for his ability to take care of himself despite it:
It’s like they don’t care. I don’t know. I’m just glad I’m healthy enough to deal with it,
because I don’t really need them that much. … I feel bad that I don’t have a relationship
with a doctor like the one I had for three years. That was the longest, and that was a good
relationship. (Then) I had (another) doctor for a year, … (and) another doctor for a
year… Then I realized that they don’t stay, and so I just keep on keepin’ on.
Some of the participants seemed to understand why medical provider turnover was so
common in the HIV field. They understood that in many cases they were being seen by residents
or doctors in training who, once trained, would leave or move on to another position within the
clinic. Others retired or burned out because, as Larry explained, “their jobs (were) very
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challenging, and we’re a difficult group of people to have to work with.” Julio accepted the pros
and cons in provider turnover: “It’s negative, and it’s positive, like I said. I think the positive is
that you get fresh people with fresh ideas and fresh techniques. On the downside, you get new
people all the time...”
Lack of Time with Medical Provider
In addition to high turnover of medical providers, the participants complained about the
lack of time their medical providers were able to spend with them. However, they voiced these
complaints in the context of the environment that the medical providers were working in. They
observed that their providers appeared overworked, which sometimes led to careless mistakes
such as forgetting to submit a referral or lab work which delayed their access to follow up
medical care. They said that the medical providers could not give them enough of their time
because they were always so busy and had to move on to the next patient. Or they didn’t respond
to their phone calls fast enough when they had a question. Nate explained:
Doctors don’t have time to sit there and talk to you. I feel horrible for the (patients) who
come in and say, “I had this thing last week, but I don’t really remember,” and then the
doctor takes advantage of the “um” and goes to the next thing. Then the client feels like,
oh, my God. I came to the doctor. It took me three hours to get here, and I didn’t even get
to say what I felt the whole time.
Larry empathized with his doctor: “I’d just think sometimes—and it’s not her fault
neither. I think sometimes (the medical office) got a habit of actually overworking people, so a
lot of times, I could see her being tired. I could see her being really tired when I go in to visit her.
It’s like any other relationship. I wanted to tell her last time I went to see her, ‘You need a
vacation’”
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Building Trust in Medical Provider and Medical Care
A positive outcome of having had many years of experience being engaged in medical
care and many different medical providers due to the turnover, is that the participants of this
study could reflect on the qualities of their medical providers and medical care that they liked,
and thus how the healthcare industry ultimately gained their trust, as demonstrated by their viral
suppression status. In other words, for the participants of this study, and as noted in the literature,
having a positive relationship with their doctor and their healthcare was key to their ability to
adhere to their medical treatment.
Qualities that build trust in medical provider
The qualities the participants liked in their medical providers included those doctors who
were direct, honest, good listeners, and someone they felt they could talk to. Others talked about
the doctors who appeared knowledgeable, competent, and simply earned their trust because they
were good at what they did. According to Fred, “I think I have a lot of trust in (my doctor). I
think he knows his stuff. He's easy to talk to. I don't think there's anything I don't like about him
at all.”
Being personal. Intimacy with their medical providers emerged as a theme during the
interviews. The participants described the provider who they felt understood them as complex
human beings and not just another patient with HIV. They further appreciated the providers who
made an effort to relate to them on some personal level, as explained by Larry: “I like (the)
relationship to be a little more—I don’t know—personal, just a little more like I’m a human
being; I’m not just a client. I don’t wanna be treated like a client.” Another example is from
Ashley who described a time when she switched providers from a male doctor to a female
doctor, even though the male doctor in that practice had more experience. She said the male
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doctor was OK but she felt more comfortable talking to the female doctor because the female
doctor would ask her questions about her life as a woman and a mother. “Once in a while we had
moments, … I guess you would call it intimacy during the relationship… It can’t help but get a
little personal where … you come in, and you gotta trust somebody, at that point, so they were
true with me. (She) noticed when I (was) having a rough day, my child this, or my husband that,
and would ask me about it.” Finally, Pamela appreciated how her provider knew her personality
and how she reacted to new information: “I think she knows my personality. She knows me
'cause we have conversations, and sometimes, she knows how, she would say to me, ‘Now, I
know you're a little anxious. I know you get a little anxious about some of these things, so I'm
just gonna tell you this so you will know, all right?’ She knows me. I feel good about that.”
Other participants appreciated the medical providers who took an interest in political
causes that impacted them directly, as members of various oppressed or discriminated groups.
Roberto said: “Well, first, I look at how and what they do for my community, my community
being Gay Latino males, and see what type of work they do within my community. That allows
me to trust them a little bit more because, if they’re advocating for us, they’re fighting for us,
then it makes me more inclined to trust them about information that they divulge to us.”
Similarly, Ashley appreciated how her doctor made an effort to advocate on behalf of African
American people living in a racist society:
My PCP, I have to say that the last two I've had, I've had a good rapport with. I could go
in there and talk about anything, and I like that… Like last time, we were speaking about
the Black Lives Matter movement, and … she actually told me that she participated in it
and how she jumped over a big barrier with some friends. I felt, that's the kind of rapport
we had. We shared things like that. I like her…
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Teamwork. Teamwork with their medical providers and within the healthcare system
was another theme that emerged from the data. In some cases, the team consisted of the patient
and their doctor: “I've learned you and the doctor become a team. You being open-minded with
the doctor, and the doctor listening to you, and you listening to the doctor, and the doctor putting
you on the right medication,” explained Malik. Similarly, Pamela said: “I started to read. I
started to get trainings and stuff like that. I think that changed my perspective as to how I
approach the doctors. I work with them now. It's not like I go there and I just gulp down
information that's just thrown at me. It's like a team thing. I work with the doctor.”
Others talked about their team of providers and the importance of coordinated care
between their primary care provider (PCP), the other medical providers in the practice, their
psychiatrist or therapist, nutritionist, social worker, pharmacist, and anyone else who is working
with them. “They work hand-in-hand together…,” explained Carlos, “the nutritionist, the
psychiatrist, the social worker, the front desk staff. … They all work hand-in-hand…”. Julio
provided an example of a time when he needed a referral. He explained that making referrals is
complicated because you need to make sure the specialist takes the insurance, is accepting new
patients, and is located in a geographically convenient location:
Referrals are the most annoying thing because let’s say you refer me to a place where
they don’t take my insurance because you’re not doing the actual work to figure out
whether or not I’m in network… She (the Social Worker) did the work… Well, their
team of support did the work because they referred me to a place that was nearby that
took my health insurance that had availability. That’s what I love about them. That’s
when the other support team…that’s where they come into play because they the ones
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who do all that work. Because the doctor’s not gonna do all the work because they have
other patients… and the team of social workers (do the work) …
The participants especially appreciated the team of nurses and other medical staff who
assisted the doctors and had more time to spend with them. They explained that these medical
providers would ask them the relevant questions and document their answers in their chart so
that their doctor who did not have the time to talk to them would be aware of their concerns prior
to meeting with them, as explained by Tom:
I definitely appreciate the nurse practitioner, the nurse who takes your vitals and stuff,
because they definitely pull out the little things that sometimes you as a client might not
even be at the forefront. You might have forgotten. Oh, I’ve had that wart, or oh, I had
that rash, but they make you sometimes step back into that thought process and then
you’re like, “Oh, thank you for reminding me that I didn’t take my meds last Thursday,
and maybe that’s why I felt sick.”
Fred appreciated how the nurse practitioners were more likely to “think outside the box”,
recommend more experimental treatment or holistic healthcare than the doctors:
Nurse practitioners (are) more willing to do experimental things: try vitamin C, try IV
drips, try different things that some doctors would say, "Oh, that's bunk. That's not gonna
work." Doctors tend to be more linear in their thinking, where nurse practitioners would
veer a little bit to the left or the right of the linearness just to make sure that you can—I
mean, I've done acupuncture. I've done IV drips. I've done other things, other treatments
—that are—and that's why I'm here 31 years later probably.
Clinic culture
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The participants talked about their relationship to their clinic or doctor’s practice as a
factor that influenced their choice of provider. They appreciated the clinics that showed them
respect, made them feel welcomed and made them feel comfortable. Malik said: “They have
gotten to know me over the years. The nurses, the receptionists… they cater to you. They call
you by your last name. They're very respectful...”. Ashley said: “I don't know about anyone else,
but for me, that's important. It makes you feel a sense of welcome like, oh, I appreciate you
coming in. I appreciate you being here. Even though you're just at the front desk, checking in, it's
still something to me.” Similarly, Carlos described his clinic as follows:
It's the best clinic. They treat their patients with respect. They offer you a coffee or a tea,
some hot water, cold water. They give you a nice chair to sit down when you're waiting
for the doctor. You get a nice, warm bench. You get a cookie or something. The doctor
walks in, treats you very nice. They're not afraid to touch you. They're not afraid to go
close to you. I feel 100 percent satisfied and not treated with scorn…
Finally, Julio particularly appreciated how his clinic made an effort to be inclusive by having
posters of different types of people on the walls: “This is just an example of something that I
love about them. You walk into the clinic, and there’s a poster that says, ‘Sex work is work.’
That’s something that I just love about them, that poster, how open they are. They really provide
a safe environment…”
Community-based organizations’ role in building trust in medical care
In addition to the medical providers and clinics where they accessed their medical care,
the participants talked about other places they went for healthcare information and support. All
of the participants were associated with a program or community-based organization dedicated to
serving PLWH. At these agencies, the participants received supportive housing, case
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management services, individual and group counseling, benefits and entitlement services, peer
support, food and nutritional services, as well as educational trainings and workshops where they
learned about HIV, medical treatment options, and other health-related information. Ian
described his program as follows: “(They have) social workers, healthcare nutritionists. They
have the nurses, and they do groups, and they do—they teach you about your health and stuff
like that. We have current events which we talk about everyday life, what’s goin’ on…”
Similarly, several participants talked about receiving support from their peers, other
PLWH, many of whom they met at these agencies during groups and/or as Peer Educators or
Counselors. Pamela spoke about how, at first, she resisted going to peer support groups because
she thought she was different, not like the other people who were attending those groups.
Because she was never homeless or used substances, she didn’t think she fit in. But she was
encouraged to join by her therapist, and eventually came to understand and appreciate the
support she got from her peers:
I'm listening to people speak. I'm hearing people say that they were homeless. I'm hearing
people say that they were intravenous drug users. These are all experiences that I could
not relate to. … But I would go, I was present. … (And eventually) you're getting
something (out of it) … It's the strength, the strength (of) the stories, the connection, that
remained with me as such a teaching point because … I had to realize that … we are all
on the same level. It's not about a person who was on drugs and somebody who was
homeless … Something brought us together. …We are here in this room … because we
all need to be. Something happened to all of us, (which is) why we are here … It is one of
the best forms of getting your life back. …Besides medication and your physical health,
the people, the power of the people is fantastic. I never regretted it. I never regretted it.
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Another source of support for some of the participants was their family. Family members
helped them stay motivated and focused on their health. Others spoke about religion as a source
of support. They described themselves as spiritual people who found strength and peace of mind
in their faith. For instance, Malik said: “It comes back to my spirituality.… My faith is my
foundation. Religion, faith, whatever you wanna call it. That carried me to where I'm at today,
and I'm not never gonna let that go.”
Overcoming Behavioral/Psychosocial Barriers to ARV Treatment Adherence
The participants of this study experienced many of the same behavioral and psychosocial
barriers to ARV treatment adherence over the course of their life living with HIV that were
highlighted in the empirical literature. They included substance use, mental illness, and
homelessness, and they interfered with the participants’ ability to take their medication as
prescribed in various ways. The following section details their experience with each of these
barriers to ARV treatment adherence and how they overcame them.
ARV Treatment Adherence and Substance Use
Several participants described their histories of substance use and its subsequent impact
on their ARV treatment adherence. Most had stopped using several years prior to the interview
and credited their abstinence from mood altering substances to their ability to adhere to their
medication and becoming virally suppressed. According to Fernando, it was impossible to do
both, use drugs and adhere to medication:
I understand people not taking medications when they’re actively using substances
because taking medications isn’t the number one thing on their mind… When I actively
use substances, specifically the ones I choose to use… Me in that mindset, no. Taking my
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meds is not a priority. Along with many other things. Being a person in society is not a
priority when I’m on substances. That’s the reason why I don’t use ‘em anymore.
Similarly, Malik said:
I did my study early when I found out what was wrong with me (being diagnosed with
HIV). I decided to do one thing, stop drinking, stop smoking reefer, stop doing all the bad
things I was doing, and start focusing on my health… Yeah. I'm not a hypocrite or one to
judge nobody. It's just like I learned early; you can't live both lifestyles. Every now and
then, you can, but you cannot consistently live that other lifestyle with doing this. It
doesn't mix.
However, other participants were active users of drugs and alcohol at the time of the
interview. Some talked about how their current alcohol and drug use impacted their ARV
treatment adherence. Ian explained that his substance use caused him to forget to take his
medication: “When I go out, and I’m getting high, and I know I’m supposed to take (the
medication) before I go to bed…, if I hang out and decide to go to a bar and everything, I will
forget to take my medication. That will be guaranteed…”. Julio, who was addicted to crystal
methamphetamine, described himself as a binge addict and talked about how that behavior
interfered with his ARV treatment adherence:
I’ve had two times (in the past year) where medication adherence was bad because … I
binged a bit longer than I should have or than I normally do… I’m what’s called a binge
addict, so I binge when I use. I don’t use for an extended period of time. I don’t use all
the time. I go on a binge, and then I come off. When I’m coming off the binge, there’s
times where I would sleep for days at a time. When I’m asleep for days at a time, I’m not
taking my meds. That’s the effect of being a binge addict.

Running Head: ARV Treatment Adherence Model

61

On the other hand, other participants believed that they were able to drink alcohol or use
drugs without it interfering with their treatment adherence. According to Fred, substance use is
not a problem as long as it is done in moderation: “I do drugs and alcohol … but I do it in
moderation. I think that’s probably what it is. I do things in moderation. Some people don’t
know how to do that. Some people can’t.” However, Melissa was concerned that her alcohol use
would cause her to forget to take her medication and therefore adjusted the time of day she took
her medication to minimize the risk: “Around (bed)time, I like to take me a glass of red wine…
I’d rather take my medicine in the daytime than at night…, I make sure I drink my red wine not
close to when I’m takin’ my medicine. I don’t know what would happen, and I want my
medicine to work. That’s why I take it at a certain time before I drink my red wine.”
ARV Treatment Adherence and Mental Health
Similar to substance use, several participants were impacted by mental illness. The most
common mental health symptoms described by the participants were depression and anxiety,
which seemed exasperated by the COVID-19 pandemic and their feelings of isolation and
separation from their community and positive social networks. According to the literature,
untreated mental health symptoms can impact PLWH’s ability to cope with life stressors, which
subsequently impacts their ability to make healthy life decisions such as taking medication to
treat a chronic medical condition (Surratt, et a., 2015). However, most of the participants from
this study did not think their mental health had a direct impact on their ARV treatment
adherence. Instead, they talked about how the side effects to their mental health medication
sometimes interfered with it. Here is an example from Nate who was prescribed sleeping pills to
help manage his depression and insomnia:
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Depression would sneak in there and sometimes insomnia and depression mixed
together—you would be asleep for a whole day. That takes advantage, and the strain is
mutating right there because you’re forgetting. Sometimes, you would sleep the whole
day, and you’re waking up at 10:00 p.m. the next day, so you missed a whole 24-hour
dosage, and you’re not even aware of it, which is even worse sometimes…
Julio described a similar phenomenon. He explained how one of his HIV medications, Symtuza,
acts as a booster to all other medications in his system. As a result, the Seroquel he took to treat
his schizophrenia made it difficult for him to wake up in the morning: “I would report to my
doctor that I would take the Symtuza and have a hard time waking up. I would still feel (sleepy)
in the morning … yeah, the mental health does affect the adherence of the medication only
because of the interactions of the pharmacology of the medication.”
ARV Medication Treatment Adherence and Homelessness
In addition to having histories of substance use and mental illness, several participants
discussed times in their lives when they were homeless and how that impeded their ARV
treatment adherence. For example, Carlos explained that because he hated being in the shelter, he
would leave as early as he could in the morning and sometimes not return until late at night, or
not at all, just to avoid being there. He didn’t like to carry his medication with him for fear of
being caught with it and having his HIV status disclosed. As a result, he would sometimes not
take his medication when he was living in the shelter: “I never liked to be in the shelter, so in the
morning, I would run out—take a shower and run out, or I wouldn't shower. Then in the
summertime, I was on the train sleeping and I never went back for the medicine, and I never
wanted to bring the medicine with me...”
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Larry talked about the sexual and verbal abuse he endured while living in the shelter,
which not only impacted his feelings of self-worth but impacted his health by putting him at risk
of contracting other sexually transmitted infections: “When I was in the shelter before, … I had
to give a blow job or someone had to fuck me before I (could) get back in the room… and (they
would) continue, continue with the abuse and the name-calling and the faggot and the this and
the that.” Acquiring stable housing helped Larry heal from the abuse he experienced while
homeless and living in the shelter, which subsequently helped him prioritize his health enough to
take his medicine and become virally suppressed.
Nobody has to do those things to me anymore. Because (of my housing) I'm settled, I
know where I can go when I want calm and I want to have no restrictions… I have my
permanent housing. I'm happy. I'm comfortable. I'm satisfied. I'm taking my medicine. I
don't care who thinks what or who wants to know what now... I can walk with a banner
over my head now to say I'm positive and proud.
Like Larry, all of the participants who had histories of homelessness were housed at the
time of the interview and were grateful for that. Similar to those who believed their decision to
stop using drugs was the primary factor that contributed to their ability to adhere to their
medication, these participants credited their stable housing for their ARV treatment adherence
and viral suppression status, as explained by Fernando: “I’m in a very good situation (now). I’m
housed (and) I’m not actively using substances...”
Personal Barriers to ARV Treatment Adherence
On a personal level, the participants talked about their knowledge, attitudes and beliefs
about the ARV medication and how these factors impacted their ARV treatment adherence. The
personal barriers included feeling overwhelmed by the notion of having to take medication for
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the rest of their life, fear of side effects to the medication, not liking to take medication in
general, wanting a break from the daily routine of taking medication, and the challenges
associated with traveling and/or needing to take HIV medication in public. Each of these
challenges interfered with the participants’ ARV treatment adherence and subsequently their
ability to achieve viral suppression and improve their health outcomes.
Feeling overwhelmed
Several participants talked about feeling overwhelmed by the notion of having to take
medication every day, for the rest of their life. This is noted in the literature as a common
response by many people diagnosed with a life threatening, chronic medical condition. As a
result of feeling overwhelmed by the need to take medicine every day, many people with chronic
medical conditions feel powerless over their disease and unable to adhere to their medication
regimen as a result (Kini and Ho, 2018). Pamela described her first reaction to the news that she
was HIV positive and would need to take medicine on a daily basis in order to live:
You never hear about a medication where, if you don't take (it), death could be—it’s
inevitable because your viral load will rise, and then, of course, you could die. … I wasn't
happy about that. I felt like it could not be done. It was unrealistic. Then, of course, the
fear stepped in because I realized that, okay, you're not gonna do this every day. It is not
realistic. There are times you're gonna forget. There are times when you're gonna get up
late. You don't want to tie yourself to this thing. That was real at first.
For some of the participants, the simple notion of having to take medication, a pill, was
the barrier. Ian said: “I didn’t used to like takin’ pills at all. I never liked pills. I hate pills and
that was one of the reasons why I didn’t wanna take ‘em in the beginning ‘cause I didn’t like
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pills… I’m not a pill head. I don’t know. I (was) afraid that—what it might do, or … how it
(would) make me feel.”
Fear of side effects
Real and perceived side effects to the medications were also deterrents to ARV treatment
adherence. This was especially true for those participants who were diagnosed 20-30 years ago,
when the earlier versions of the ARV treatment, or cocktails (complicated medication regimens
requiring multiple pills that needed to be taken at various times of the day), as they were called
back then, were “toxic horse pills that made (them) fat”. Besides having chronic diarrhea or
constipation as a side effect to the medications, they talked about the damage that the
medications did to their kidneys, liver, and other organs. According to Fernando: “they made my
eyes yellow.” And they talked about how the medications changed the shape of their bodies
because it altered how their bodies stored fat. When Ian found out he was HIV positive, his first
reaction was:
Oh, my God, I said, “I’m gonna die now.” I’ve seen people who wasn’t looking too good.
Some people turned gray; some people had lumps in their back. They had big lumps in
their back, on their shoulders, in their arms, a big knot will come up on ‘em, and stuff like
that. I forgot what they call that, but yeah, they was getting those side effects. That’s why
I was saying, everybody was getting all different kinds of side effects and I was scared,
‘cause I didn’t wanna get those side effects.
However, for the most part, side effects were not a present barrier for the participants of
this study. Most were only taking one pill a day for their HIV at the time of the interview, and
they said the pills were less toxic and much smaller than they used be. They also said that
eventually their bodies got used to the medications and the immediate side effects went away.
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However, Ashley said she was still concerned about long-term side effects to the medication, or
more specifically, the lack of knowledge about the long-term side effects.
Forgetting to take the medication
Regarding taking the medication on a daily basis, the participants talked about times in
their lives when they were busy or dealing with personal life situations which would cause them
to forget to take their medication. Tom said: “Just work, school, juggling a lot of different
(things) that comes up in life where unexpected events come up or circumstances. I got to run
and take care of my sister or run and take care of another family member, and then I just don’t
think of it until the next day.” Similarly, Ashley explained: “It was outside forces. It was a
stressful family situation. I actually couldn't remember whether I did or didn't (take the
medication), so I forgot to take it 'cause I couldn't remember if I did take it or didn't...”
Forgetting to take their medication was a common theme among the participants.
Everyone talked about times when they forgot to take their medication. Fernando specifically
referred to the time of COVID as a time that was so overwhelming and unusual, that he forgot to
take his medication because he didn’t know what day it was. “In the beginning of COVID, I
forgot so many days ‘cause you’re just in your house and you’re like, bleh, especially when we
were here in March and April (2020). We were all - what day of the week is it? What month?
What the fuck is happening? All that shit. There were multiple days that I forgot to take my meds
just ‘cause of everything.”
Making a choice to not take the medication
Others talked about making a conscious decision to not take their medication because
they were “bored” or “tired” of the daily routine. They were told by their doctors that it was OK
to miss one pill or one day here and there, but that they should not miss more than that to avoid
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developing resistance to the medication. Despite this advice, a few reported going off their
medication for longer periods of time, just to see what would happen, as Melissa explained:
It was to the point where I didn't take it 'cause I wanted to see if I could do it on my own,
like changing my lifestyle a little bit, whether I could get it to stay undetectable. That
didn't last very long. Because I also told my (medical) provider I was doing it, and she
couldn't talk me out of it. She said she didn't recommend it. She said the most was a day,
but I actually went two weeks without taking it, and then when I went back (to the
doctor), it was—I think … my viral load was 98 or 100 and something.
An undetectable viral load is a viral load of < 20 copies, which means this participant was no
longer undetectable when she went off her medication. The problem with stopping their
medication for periods of time more than a day or two is that the virus can mutate and the
medication that they were on might stop working or not work as well. Evelyn learned this the
hard way. When she stopped taking the medication, she developed resistance to it and needed to
start a new medication.
I'm taking it every day, every day, every day, two times a day. I just got tired of taking
medication. For about six months, I didn't take the medication. It felt good. But
eventually, I had to go back to taking it, and then they had to change it because it wasn't
working because I had stopped taking it so long… Now I know I can't do that no more,
play with my health. Back then, I was like, I just didn't wanna take medication no more. I
was just tired.
As noted in the empirical study on financial incentives (Ghose, et al., 2019), Fernando
also described the situation where PLWH would not take their ARV medication so that they
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could sell it for the money. While he said he didn’t do this himself, he empathized with people in
these situations:
I’m sure you know, a lot of people who are experiencing homelessness and everything.
There are some other important things, like food, some type of security. There is a known
thing of selling your HIV medications and not taking them, that is definitely a motivating
factor for not taking them—the monetary value of them…If you’re in that state of mind
and you need money now. I understand that motivating factor of not taking your
medications.
Taking medication in public
Finally, taking medication in public or traveling with the medication was a common
challenge mentioned by the participants, which seemed related to their fears associated with HIV
stigma. As Nate stated: “It’s like who’s seeing, who’s around me, who would know. I don’t
wanna get caught taking it. I don’t want them knowing that I’m HIV-positive…” Malik
described a time when he went through Security at the airport and the TSA agent opened his
carry-on and publicly asked him about his bag of medication: “When you go in the airport you
have to travel with your carry-on. The airport (Security) go through your stuff and question,
‘What is this?’ It's my medicine. Some of them take it out (of) the bag and read it, whatever.
Some don't. Some do. There's a paranoid state coming.” Carlos talked about needing to adjust his
routine during times when he had a guest in his apartment: “There's one part that's very difficult
is having company. You have to, before they come up, hide your medicine. You (can’t) go
through your normal procedures… 'Cause you don't want people to know— Yeah, if you have
somebody with you, you have to wait for them to go in the bathroom (to take your medication).”
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Finally, Pamela talked about a time when she was with a family member who she didn’t trust
knowing about her HIV status:
You don't tell everyone your business, even though—even if it's family. You just don't
want them to know 'cause it's none of their business. You have to have that good feeling
in your spirit to share with them what you're going through. A particular family member,
I didn't have that with. … We were in a closed setting, (and) it was very hard for me to
navigate to take (the medication). I had to literally turn around and pretend I was digging
for a piece of candy. I put the pill in the same time as the candy, which was horrible
'cause (the candy) was big. Then trying not to swallow the candy whole but swallow the
pill was stupid. It was dumb. … The things that I went through just to try to hide it, … I'll
never do that again…
On the other hand, other participants talked about how their comfort with taking their
medication in public changed over time. In the beginning, Fred said he was self-conscious about
it and would go to great lengths, like the ones described above, to avoid taking the medication in
front of other people. But today, he no longer feels that way or cares what other people think.
“I'll go out to dinner with friends, and I'll put 'em out on the table. If I'm eating dinner at that
point, I'll take 'em, knock 'em back, drink the water or drink the juice, and then call it a day.”
Similarly, Larry said: “Say, if I’m hangin’ out at a party at night, if it’s 9:00 and I know I’m
supposed to take my meds, and people around, I used to feel uncomfortable with just takin’ my
meds and poppin’ ’em in my mouth. To me, the whole room’s gonna watch me, so I may not
take my meds then... Now, I’m to the point it doesn’t matter.…” Finally, Ian described another
person’s reaction when he took his medication in front of others during a Narcotics Anonymous
(NA) meeting:
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One day I was sharing at a NA meeting, and I had forgotten to take my meds that
morning, so in the middle of my sharing, I was like, “Oh, shoot, I forgot to take my
meds,” so in front of all these people, I pop open my pill bottle, and I didn’t think nothing
of it. I took my meds. When it came to the sharing part, a girl raised her hand, and she
said, “Thank you.” I said, “For what?” She said, “I never seen nobody do that. In the
middle of your share, stop and take their medicines.” She said, “Thank you for showing a
positive example of takin’ care of yourself.” She put her hand down. I said, “Thanks for
letting me share”. I just wanted to say that.
Overcoming Personal Barriers/Building Self-efficacy
Despite facing numerous structural, behavioral, and personal barriers to ARV treatment
adherence, the participants of this study adhered to their ARV treatment medication, as
evidenced by their viral suppression status. This section describes how the participants built their
self-efficacy to take their medication as prescribed. It started with a need to accept their chronic
medical condition and their need to take their medication in order to survive, despite the
challenges. It also involved a process of changing their perspective about the medication from
something one takes because they are sick to something one does to keep themselves healthy.
This section also includes a sub-section detailing what it means to be an empowered consumer of
healthcare. Finally, this section on self-efficacy concludes with several concrete strategies the
participants developed over the years that help them remember to take their medication and
travel with it.
Acceptance of condition
Every day, the participants of this study make an active decision whether or not to take
the ARV medication that stops the HIV virus from replicating in their system and keeps them
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alive. In the process of deciding to prioritize their health and take their medication as prescribed
(overcome the barriers), the participants talked about the need to change their perspective about
the medication from something they had to do because they were sick, to something they did for
the good of their health, as explained by Pamela:
When you look at the medication, you know it's a pill that you have to take, and that is an
acceptance. You're taking a pill. A pill reminds you that you have something wrong with
you. Then I think, … I started to change my perspective to how I saw a pill because I did
take multivitamins. I did take other things to keep myself healthy. I think I learned along
the way too, it's part of your health. You don't see it as a negative. You see it the same
way you will look at a multivitamin, the same way you would look at an herbal tea, and
you see it as something that you are doing for the benefit of your life. … I think that is
what has kept me taking it without feeling like it's a burden.
Julio talked about striving to reach a point where he no longer felt like the virus was
managing him but rather, he was managing his virus: “I wanna live my life and manage my
health. I don’t wanna live my life managing my health… I wanna be able to feel like I live a life
outside of my condition, that my condition doesn’t define me.” Similarly, Melissa described her
relationship with HIV and the ARV medication as a need for balance: “(I’m) trying not to let this
disease take over my life… The word balance is what healthy means to me. Being able to give
myself just what I need (to) keep myself alive.” Finally, Larry called it responsibility: “It's called
responsibility. I’m responsible for my health. Nobody else gotta be responsible for me every day.
When they are, when they do have to be responsible, it’s ’cause I can’t do it no more. But while I
can do it, I’m gonna do whatever I gotta do so I can have a quality of life like everybody else
has, so I can walk with some dignity.”
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Empowered Healthcare Consumer
When asked about their process for making decisions about their health, all of the
participants talked about how they would talk to their doctor. However, the participants also
talked about the need to do their own research regarding their healthcare and how the final
decision regarding how to proceed with their medical care was up to them, not their doctor. This
was understood as an example of their transformation from being a passive recipient of
healthcare to an empowered consumer, or someone who refused to be disempowered by their
medical condition. The participants explained that they would research healthcare information on
the internet or read pamphlets or magazines they picked up from their doctor’s offices or at the
community-based organizations of which they were a member. Many of them also attended
workshops and trainings provided by their programs and some even went on to become peer
educators at their organizations and taught others.
Credibility of source. The credibility of the source of healthcare information was a
common theme from the interviews. When searching for information online, the participants
mentioned specific websites they would go to such as WebMD, AMA, or a government site such
as science.gov, the FDA, or NIH, that they would trust over others, as explained by Julio: “You
have to do your own research and know where to research because lotta people read blogs and
Wikipedia. … You have to be a truth seeker. People believe just about anything. They’re
willfully blind because they don’t wanna do the research. I’m not one of those people”. Fred
explained: “A credible source would be somebody who's reliable, doesn't seem to be one who is
actively using drugs and seems to be reliable. Then, I'll question my doctor on it, or I'll look it up
online and say, ‘Is this a medication I'm interested in or not?’”
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Actively engaged in care. Taking an active role in their healthcare was another quality
of an empowered healthcare consumer, as described by the participants. They talked about how
they would ask a lot of questions to try to understand the science behind the medical treatment
and not take information at face value. Malik stated “You just can't (say) God is gonna help us,
or rely on the doctors. (You need to) know whatever they know, their skill set. Listen to them
and also … question them. I'm always questioning things. I'm not a, oh, go take this pill and
you'll be better. No. What is the pill gonna do to me? Where is it coming from? How's it gonna
help me? I like the science.”
Having an interest in the medical and scientific aspect of the virus and treatment was a
common trait among the participants. When asked if they believed the medicine worked, they
said that they did because they would study their labs and research anything they didn’t
understand, indicating their investment in their healthcare and the process: “I’m getting my labs
back and researching the numbers, reading the bottom of the paper—where they have the
explanation of what your results mean, and if it's something I don't understand, I'll Google it,
find out, what did that mean that they're saying?”, explained Ashley.
Based on the lab reports, they learned that their viral loads would decrease when they
were on their medication and increase when they were off it, unless they were sick which also
might cause their viral load to increase temporarily. Evelyn explained that, at first, she didn’t
understand that the lab test could detect if she was on or off her medication and would lie to her
doctor when her doctor asked her if she was taking her medication. When she said yes, and her
doctor would then question her about it because the data indicated that she wasn’t, she realized
they were connected.
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One time I got tired, and I stopped taking (my medication). My T-cells went down, and
my viral load went up. My doctor, I never said nothing. They was taking my blood, and
stupid me, I didn't know you can look in the blood and see that you're not taking (the
medication). I didn't know that. Then they looked at my blood and they were like,
"You're not taking your medicine?" I'm, like, "Wait, yes, I'm taking my medicine." He
said, "Well, your viral load's going up and your T-cells going down. Why is this?" Then I
had to admit that I wasn't taking it … Now I know I can't, I have to keep taking (my
medication) so, at least they helped me. Now I guess my mindset is different.
Fred explained what he learned from the workshops he attended in his building where he was
living, which was a congregate housing facility for formally homeless PLWH:
Well, I read literature. I went to workshops …They (had) a pharmaceutical company
come in and do workshops with us with video slides… (They) would show the virus
mutating if you don't take (the medication) properly and it not mutating as much or
multiplying (if you do)—also, knowing that the pill I take has three different—it catches
the virus at the cell wall, inside the cell, and as it exits the cell. That means it's helping to
keep it suppressed. And I've noticed the numbers. My numbers have been down when I
(take my medication)—since I have been taking it regularly.
Finally, having a grasp of the science was a recurring theme among the participants. “It's
my logic,” said Fred, “…if it makes sense to me scientifically—'cause as I told you, I like
science. If it makes scientific (sense) to me, it's like, okay —that light goes off and I say, ‘Yeah,
maybe that could have some validity...’" Similarly, Carlos explained: “You look at the resources,
you look at how (the) studies work, were conducted, that type of stuff. If you see opposing
opinion or fact or whatever, you just look at the amount of the information. If you have 10
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articles saying, yeah undetectable means you can’t transmit it, versus one, where it’s like, ‘No,
that’s a hoax.’ It’s 10-1. Okay. What do you believe?”
Not being a follower. In line with being an active participant in their healthcare, the
participants talked about the importance of making decisions based on their own experience and
assessment of the situation, and not being a follower or doing whatever they were told to do,
either by their doctor or someone else. “I rely on my gut”, explained Fernando. Likewise, Ian
said:
When I first got diagnosed with HIV, I started doing groups, support groups. Everybody
had different feelings about (the medicine), and different (side) effects. So I realized that
so many people had certain effects that I didn’t (have). I know what’s real and what’s not,
‘cause I realized everybody’s body is different. My body was—is different than other
people that broke out from (the medication), and got rashes, and all kinds of different
things people experience. I realized not to go by other people, but (to go) by my own
experience.
ARV treatment adherence strategies
Accepting their disease and need to take medication to survive was the first step towards
building self-efficacy to adhere to their ARV medication. The second step was to become an
empowered healthcare consumer and educate themselves about the medication and the benefits
of taking it. The third and final step in this process involved developing concrete strategies that
helped the participants remember to take their medication as prescribed.
Having a daily routine. Every participant talked about the importance of having a daily
routine when it came to their ARV medication and other medications they were prescribed and
needed to take on a daily basis. Larry used words like “robotic” and “automatic” to describe the
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process: “For the most part, you just set a routine. That’s where the robotic stuff comes in at
because it’s an automatic thing. (I) reach over there on my bed and grab some meds and pop ’em
in my mouth and drink some water. That’s how simple it is…”. Fernando explained: “Everyone
develops their own habit. Whatever works, … Some people keep it in their bathroom cabinet
thing. Some people keep it in their kitchen. For me, I always keep it on my—I call it my
medicine table—and on the lower level is my actual medications and on the top is my weed.
That’s my medicine table.” Finally, Pamela explained that making treatment adherence part of
her daily routine was advice she was given early on, at a time when she was struggling to remain
adherent. The person advising her asked her what it was she was already doing on a daily basis:
“I said, ‘I brush my teeth. I say my prayers every morning. … I have breakfast.’ He said, ‘There
you go, …that's it.’ He said ‘taking medication has to come just like something … you do every
day. … Taking medication becomes another thing that you're doing, but just along with (what
you are already doing)….’”
Taking medicine at the same time every day. Most of the participants insisted that
taking the medicine first thing in the morning was the way to go, a good way to start their day.
Malik said: “In the morning, it's like a booster for me. It boosts me. It gives me the agility that I
need to get my day started like somebody drinking a cup of coffee. That's my coffee.” Ashley
explained that she liked to take the medication first thing in the morning before she got busy
doing other things, so as not forget to take them:
'cause that's when my day starts, and I just—every morning, I get up, … That's my
routine. Morning, I just take pills. Yeah. I think, as the day goes on, you may be trying
to—you may forget 'cause you get involved in other things. You live life. You'll be like,
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did I take that pill this time? Do I have to take it? I just decided to get it—do it first thing
in the morning when I get up. It's easier that way for me.
Pamela on the other hand preferred to take her medication at bedtime: “Evening time or
night ... I'm going to relax. I'm going to bed. I know I like my late-night shows, so as I start to
relax, I know I had dinner already. I had whatever I had, so I'm gonna take (my medication). This
is my relax time now, so I take it then 'cause I'm not going anywhere. I'm not gonna do anything
else.” Carlos explained that he believed the medicines worked better when taken at night:
“Because in the daytime, I do a little activities, and then in the nighttime, I just go to sleep. So I
guess if my body's resting, the medicine is getting absorbed better. I think that's just in my head.”
Finally, Evelyn explained that she uses the nighttime as her back-up option in case she forgets to
take her medication in the morning: “If I miss it in the morning, I take it in the nighttime, so I
know I will have taken what I need to take for the day. So I make up for it. I make sure that I
have it. I think in our training somewhere, they told us you can do that, like if you didn't take it
in the morning time, you can take it in the nighttime.” Finally, Julio didn’t like taking his
medicine on an empty stomach and therefore associated taking his medication with a specific
meal of the day: “I never forget to eat. I love food. Part of my adherence was associating a meal
with my medication regimen.”
Setting reminders. In addition to developing strategies so that taking their medication
became automatic or part of their daily routine, some of the participants used technology to help
remind them to take their medication. Nate mentioned that he schedules his Alexa device to
remind him to take his medication. He also talked about an application he downloaded from
Gilead, an HIV pharmaceutical company that manufacturers several ARV medications, that is
designed to text reminders to PLWH to take their medication: “I have alarms. Gilead HIV
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service has an app, so I take advantage of their mobile texting alert. It also has little weird
phrases, like ‘slay’, ‘go to work’, ‘it’s hammer time’—little things to remind you to take your
meds, but that I don’t have to see the words ‘take your meds’ on my screen.”
Tom explained that although his treatment adherence is now routine, he uses alarms and
other technology to help him remember, just in case: “It took a lot of work…, it took a long time
for me to implement into my regimen where I don’t have to think about (taking my medication),
but I still put in the alarm and the alerts and stuff, because we are human and there are days
where we forget…” Finally, Ian talked about how he used to have a friend who would remind
him to take his medication every day. That was until it became automatic for him and he didn’t
need the external reminder. Now he uses his daily exercise routine to help him remember to take
his medication: “In the past, I had—not a lover, but I had a close friend or roommate remind me
in the beginning of the time, ‘Did you take your meds?’ (Now), I incorporate (it), more than
ever, working out helps me. I am now really good at taking the HIV pill at 10:00 every day.”
Using the pillbox. Most of the participants used a pillbox to assist them with their
medication adherence. A pillbox, also called pill pack or pill case, is a container used to organize
one’s medication doses for a certain period of time, usually a week, with each day of the week
labeled by day. This way, they place all of the daily medications in the appropriate box and use
that to monitor whether or not they took it. According to Tom: “When it’s empty, when that day
is empty, there’s nothing there, then that signifies—that shows me that I took my medication that
day. When I don’t have that and I’m just taking it straight out of the bottle, I’m not sure if I had
(my medication) or if I didn’t have it.” Participants who liked the pillboxes explained that they
not only helped them monitor whether or not they took their medications each day but were more
discreet and easier to travel with than the pill bottles. Nate said: “I’m also grateful that we have
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pill packs, so we’re able to take the pill packs. It’s a little more discreet. I can hide them more
places, opposed to the pill bottle…” Nate also appreciated how he is able to clip his pillbox onto
his keychain, which helped him improve his treatment adherence.
However, Fred did not like the pill box. “…I don't like those pill boxes. First of all, they
don't work for me. They're not as easy to grab and go unless I take the whole seven days with me
all at once...” Fred developed his own system for monitoring his treatment adherence. He
explained how he would take all of the pills he needed to take for his various medical conditions
and would separate them into different pill bottles, one for each day of the week. So if he was
going out for just one day, he would just need to take that one pill bottle with him for the day as
opposed to a whole pillbox.
Tuning into your body. Finally, several participants talked about how they could feel
the medication in their system and would know when it was time to take their medication by
being tuned into their body. Nate explained that he would feel different, or experience
symptoms, when the medicine was not in his body, which would signal to him that it was time to
take his medication.
My experience is that I feel like I’m withdrawing. You can feel like the medicine’s not in
your body. It sounds crazy, … but because I’ve been on so much medication, literally,
my body has learned when a medicine is not in the body. Before the alarm could go off, I
start getting the aches and the pains… I feel different, my mood changes. Maybe I have a
headache or migraine that day. If I don’t take my meds, I definitely know it.
Ashley explained that it wasn’t her ARV medication but rather her high blood pressure
medication that would cause her to have symptoms when it was time to take her medication. She
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therefore decided to tie her ARV medication to the high blood pressure medication and take
them both at the same time.
It's easy. I just combine it with what I already take. I take high blood pressure meds, so I
take that pill with that... I know I have to take my blood pressure meds or else my head
starts hurting. I just know when I forget to take my high blood pressure pills 'cause my
head hurts, so it's easy. If I want to avoid those headaches coming on, I take my high
blood pressure, and I put the HIV med with that, and that's it. It's easy for me. It's just
having an extra pill to take every day.
Motivation
The participants of this study clearly expressed the importance of being able to trust their
medical provider and medical treatment, and how this trust influenced their ability to adhere to
their ARV treatment and achieve viral suppression. They further discussed how they
strengthened their self-efficacy to overcome the day-to-day challenges they faced with
medication adherence. However, none of this explains why they made the effort, or what
motivated them to overcome the barriers to ARV treatment adherence. The simple answer to the
complex question what motivated the participants of this study to overcome the structural,
behavioral and personal barriers to ARV treatment adherence was that they wanted to live; they
didn’t want to die. When asked to elaborate on that, the participants described a variety of factors
that contributed to their motivation. This section offers a more nuanced understanding of what it
means to want to live. More specifically, it explores what it means to have to make a decision on
a daily basis to take medication for a chronic condition in order to live.
Motivated by history of illness
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Several participants talked about memories of being sick as a factor that motivated them
to take their ARV treatment medication to stay healthy today. Fernando described a time in his
past when he was really sick: “It was really intense. I couldn’t walk for a block or two without
throwing up for a few weeks. It was very, very rough… Knowing how that felt, and not wanting
to ever go back there ever again, is definitely a huge thing of making sure I keep up with my
medications ever since.” Similarly, Carlos reflected on a time when he was hospitalized because
of his HIV: “Something like 20 years (ago), I fell into the AIDS stage. I got very sick. Very, very
sick. I was hospitalized for nine months with the AIDS, … I don't wanna go back to those days.”
Finally, Larry talked about a time when he was so sick, he ended up in a nursing home and then
from there had to live with his sister who helped nurse him back to health:
I was very sick. Looked like I had leprosy. I had stuff all over my body. It got ugly. I
ended up in a nursing home, … way upstate somewhere. I ended up in a nursing home,
rolling around in a wheelchair, and them folks in there said, “We see folks like you, and
they never get outta here.”… I couldn’t do anything because my mind was so depleted
from the disease. My mind, basically, was dead... I’m gonna estimate. I think, after takin’
the meds, (in) probably about six months, I started feeling better.
Motivated to live a healthier life
The participants talked about how their decision to take their ARV medication was tied to
their decision to lead a healthier life in general, to reduce or minimize harm to themselves and
their bodies. They talked about decisions they made to stop living a risky lifestyle, such as using
drugs or going to sex parties, and to prioritize their health. In the following passage, Malik talked
about making a conscious decision to live a healthier life:
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'Cause I was livin' crazy and wild… I do believe there is a supreme being that loves you
enough, that he'll give you a choice of life or death. I chose life. In my own way, so when
that happened, and I kept tryin' to (continue using drugs), and I found that the medication
wasn't agreeing with me. Then I had to make the biggest decision of my life. Are we still
gonna party and take the meds, or are we gonna just leave the party alone and take the
meds?... I had to make a conscious decision of what I wanted to do. That's the conscious
decision that I made, to stop livin' crazy and start livin' more healthy and spiritually.
Similarly, Evelyn explained that finding out that she was HIV positive and therefore
infected with a fatal disease, motivated her to want to live, as opposed to when she was using
drugs and didn’t care if she lived or died: “Because once I became positive, people would say,
‘Oh, you're gonna die now. Once you get that, you got the monster. You gonna die. You gonna
die real soon.’ I didn't want to die, so I started taking care of myself. It had to take that
(becoming HIV positive) because before I didn't care. I was using drugs. I didn't care if I lived or
died.” Finally, Ian explained he changed because he was terrified of what might happen to him if
he didn’t change his lifestyle. When asked what he was scared of, he said: “Being a bum, being
homeless, going to jail, a lot of things.”
U=U: Motivated by a desire to protect others from becoming infected with HIV
Within the past 5-10 years, the message about U=U (Undetectable = Untransmittable) –
or the knowledge that HIV cannot be transmitted to other people via sexual intercourse if a
PLWH is undetectable – has been widely promoted by the department of health and the
community-based organizations that serve PLWH. The expectation is that this knowledge about
U=U will motivate PLWH to take their ARV medication and become undetectable, which would
subsequently minimize the incidence of HIV. When asked, all of the participants were aware of
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the slogan U=U and to varying degrees had some understanding of the science behind the
statement. Some felt that this knowledge contributed to their motivation to adhere to their
medication. They believed that knowing that they could prevent others from becoming infected,
in addition to being released from the burden of having to disclose their HIV status to their
sexual partners, and be able to have sex without a condom, strongly factored into their decision
to take their ARV medication. As Pamela explained, “It is the closest thing (we) can get to not
having anything (at all).” Similarly, Fred said:
Yeah. I've been more aware of it. I've been more conscious of it. I've been more
conscientious of it because sex is my drug of choice, so that means if I want to be sexual,
I have to protect the other person, and if protecting them means keeping myself healthy
and knowing that if I keep myself undetectable, I'm not infectable, then I'm gonna work
with it... If I'm gonna have sex without a condom, which is my primary way to (have
sex), then I don't have to—I don't have any reason to not take (my medication) — I have
another reason to stay undetectable.
Ashley learned about U=U by attending a workshop at her program. She described the group’s
reaction when the science was presented: “They were letting us know that this is what the new
reality is, that, if (you’re) undetectable, you can't transmit it... Everyone then screamed bareback
(sex without a condom). Yay! Bareback is like, woohoo! Now they don't have to worry about
that rubbery feel…”
To reinforce their confidence in the message, several participants discussed personal
experience with U=U. They personally had sex without a condom with an HIV negative person
who did not become HIV positive afterwards, or they personally knew serodiscordant couples
who had unprotected sex and did not transmit HIV. For these participants, this knowledge, in
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addition to the research they read about or learned from workshops or trainings on the subject,
helped convince them that they were safe from infecting other people as long as they maintained
their undetectable status. For Carlos, “It's very important because if I stay undetectable, under
20, I can go have sex with who I want. I don't have to disclose my HIV status because I know
that I can't pass the virus on. So they can't stick their finger in my eyes and say, ‘Alright, you
gave it to me.’”
Still, it is clear from the data that the topic of U=U is complicated. While some of the
participants were celebrating this new knowledge, others were more skeptical and less likely to
change their behavior with regard to condom use and other long-established strategies that
prevented the spread of HIV to others. For the participants who had been living with the virus for
many years, during times when this knowledge was not available, and who were conditioned to
believe that if they were to have sex, it was their responsibility to use a condom to protect the
other person, they were not willing to take the risk, despite their knowledge of the science. They
talked about believing U=U “not 100%... mostly yeah, but not 100%... maybe 90%”. Larry said:
“Yeah. I don’t wanna really be doin’ that to people, really. That’s why I said knowledge is
power, so me knowing all this stuff, I wouldn’t... I wouldn’t just have sex with somebody
without a condom ’cause they still can get it.” When it was stated that the science has
demonstrated that as long as he is undetectable he cannot transmit the virus to others, he said “I
know that, (but) it ain’t gonna be an excuse for me to do that. I wouldn’t do that to nobody.”
The participants also described scenarios that challenged the science or made the subject difficult
to navigate in the real world, as explained by Julio:
I believe that, if you’re undetectable, then you’re untransmittable. …The only issue (I
have) with that is that, within (a) 6-month period, there could have been a blip where
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your viral load did go up and then came back down. I feel like if you are not engaging in
risky behaviors … then you should be good… (But) if you are engaging in risky
behaviors—and by risky behaviors, I mean multiple sex partners, substance abuse—then,
yes, you might have blips in your viral load. That might be the only thing that people
don’t understand. … If you’re engaging in risky behaviors, … then you might just—even
if you’re on ARVs, you can still, probably, transmit the virus to someone…
Finally, Tom worried that U=U was sending the wrong message to the next generation
who didn’t grow up during the height of the HIV epidemic, before we had the science to treat the
disease and slow the spread of the virus: “It only gives permission to have wild sex... I think it
gives the wrong idea to some young people. It gives the wrong idea as if it’s okay for them to be
promiscuous. It gives sort of a mixed message.”
Motivated by a life goal
Finally, and possibly most importantly, the participants talked about having something to
live for, a goal they had not yet accomplished, as their motivation for taking their ARV
medication. They needed to take their ARV medication in order to stay alive long enough to
accomplish their goals, such as going back to school, getting a job, or writing a book. Ian
described himself as an artist and a photographer and he credited his art as his purpose in life:
(My art) gives me a sense of pride. Yeah, it helped me out a lot. It gave me a purpose,
and that’s what helped me with the HIV…My artwork is (my) purpose, why you’re here
on this earth. A lot of people don’t have a purpose, so I’m definitely blessed to have a
purpose ‘cause I’ve seen a lot of my friends, and people, without purposes, and they die
real early… Because doing art and my photography, I have to be alert, and to be alert is
to be aware. To be aware is to be alive.
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Evelyn and Ashley talked about wanting to stay alive for their family. Evelyn explained
that her husband was incarcerated and that she needed to take her medication so that she would
still be alive and healthy when he was released from prison. Ashley talked about her children and
how she needed to live long enough to watch them achieve their goals:
I want to live, first and foremost. I always say I want to—even when sometimes I'm
feeling down, I tell myself, don't you want to see your daughter walk down the aisle?
Don't you want to have a grandchild? … These things. I love being here. I know for
a fact that not taking (the medication) will take me out of here, and that's something that
is not even in my thought.
Finally, when asked if there was ever a time in his life when he did not feel motivated to take his
medication, Roberto said:
I would have to say yeah, I felt that way, not to take it, but I still wound up taking it
because I know I have a purpose for taking it. I've already told myself, this is what you
have to do if you want to live. In my mind, I'm thinking, this is a life pill. This is a life-ordeath pill that you're holding in your hand. If you don't take it, if you don’t want to take
it, then you decide that you want to die, that I want to die, and that's not what I want.
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Chapter 5: Discussion and Conclusions
The findings from this qualitative study based on Constructivist Grounded Theory
provide context and depth to the known barriers and facilitators of ARV treatment adherence
discussed in the literature. Grounded in the lived experience of low-income PLWH of color who
had successfully achieved viral suppression, the findings fill a gap in the literature that
acknowledges and appreciates the complexity of medication adherence for a life threatening,
chronic medical condition such as HIV. The findings can inform the development of a more
comprehensive and effective approach to facilitating ARV treatment adherence for low-income
PLWH of color, to improve their health outcomes and help end the HIV epidemic for society.
The theory that emerged from the data is presented in Fig. 1. The ARV Treatment
Adherence Model. Data analysis revealed four factors that helped facilitate ARV treatment
adherence for this vulnerable population: 1) access to culturally competent quality medical care;
2) trust in medical provider and the ARV treatment; 3) self-efficacy to take medication as
prescribed, and 4) the motivation to take it. However, none of these factors alone appear to be
enough to overcome the competing structural, environmental, psychosocial, and personal barriers
to ARV treatment adherence. Each facilitator of ARV treatment adherence appears equally
important and interrelated to the process associated with successful ARV treatment adherence.
For example, having access to culturally competent, quality medical care alone will not help a
PLWH adhere to their medication if they do not also have the self-efficacy or motivation to take
their medication. Similarly, they may be motivated by a desire to live or survive, but they do not
trust the medication to help them achieve that goal. The model suggests multiple points of
intervention at the macro and micro levels for medical and social service providers to enhance
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and strengthen the interrelated facilitators of ARV treatment adherence while minimizing the
competing barriers.
Access to and Trust in Healthcare
The findings from the study revealed how the competing environmental and structural
barriers from within the healthcare industry directly impacted the participants of this study’s
access to medical care and their continuity of care. For example, the participants talked about
their struggles with health insurance that at times, for bureaucratic reasons, stopped covering
their treatment, forcing them to change providers or be out of care until the health insurance
company could address the issue. These barriers also interfered with the trust relationship
between patient and doctor. For example, the participants noted that their medical providers
changed often, due to high turnover of medical provider in the HIV medical field. They also
complained about the limited amount of time their doctors could spend with them, due to
financial constraints on many community clinics that serve low-income patients and the clinics’
need to maximize revenue by serving a higher volume of patients. While the participants of this
study still valued and appreciated their relationships with their providers, several learned that
they could not rely on them as a result of these structural barriers and needed to develop their
own strategies for maintaining their health without consistent support from a medical provider.
Another environmental barrier that interfered with the participants’ access to and trust in
healthcare was HIV stigma. These experiences left the participants feeling diminished and
disrespected. Feeling stigmatized and devalued made it harder to stay engaged in medical care
and motivated to adhere to medication treatment. Due to assumptions made by their medical
providers about who they were and with whom they had sex, some participants were further
given inaccurate information about their medical care, increasing their risk of reinfection and/or
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of spreading the virus to others. As a result of these experiences of HIV stigma and other forms
of discrimination in the healthcare setting, PLWH are less likely to remain engaged in their
medical care, thus impacting their ability to adhere to their ARV treatment and achieve viral
suppression.
However, findings from this study revealed aspects of the healthcare industry that worked
for the participants of this study, and therefore enhanced their access to and trust in their
healthcare. These included qualities in their medical providers that they liked, such as those
providers who were competent at their jobs, knowledgeable, and direct with them. They
appreciated the providers who were willing to be personal and intimate with them, who took the
time to understand their personality, and who got to know them as whole people and not just
another patient with HIV. They also appreciated the teamwork they observed at their clinics,
with them being an equal member of the team, along with all of the other providers and clinic
staff engaged in their care. Finally, a supportive, respectful, welcoming, and inclusive clinic
atmosphere was very important to the participants of this study, which helped strengthen their
trust in the medical care and motivated them to adhere to their treatment.
Self-efficacy
The psychosocial and behavioral barriers, such as substance use, mental health and
homelessness, experienced by the participants of this study directly interfered with their selfefficacy, or ability, to adhere to their ARV treatment to achieve viral suppression. However, for
the participants of this study, mental illness was, for the most part, a barrier caused by
pharmaceutical interactions between their mental health medications and the ARV treatment, and
not specific to their mental health diagnosis. The medication interactions caused extreme
drowsiness and extended periods of sleep, causing them to miss a dose of their ARV medication
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as a result. On the other hand, active substance use contributed to them forgetting to take their
medication or selling it to support their addiction. Similarly, their experience with homelessness
and living in a shelter impacted their ARV treatment adherence directly and indirectly. In one
scenario, a participant chose to not return to the shelter because he hated it so much, causing him
to abandon his medication and therefore not be able to take it. In another, a participant was
harassed and abused while living in the shelter, impacting his sense of self-worth, and thus his
motivation to prioritize his health. For these participants, having stable housing and being able to
abstain from mood altering substances, or at least moderate or control their substance use, were
key factors that contributed to their self-efficacy, or ability to prioritize their health and adhere to
their medication.
In addition to strengthening self-efficacy by addressing the psychosocial and behavioral
barriers to ARV treatment adherence, the findings from the study revealed how personal barriers
can interfere with PLWH’s self-efficacy to take their medication as prescribed. The data from
this qualitative study further uncovered the complexity of the concept of self-efficacy for ARV
treatment adherence. Most people take medication because they are sick, and as one participant
of the study explained, that means there is something wrong with them. However, the purpose of
taking medication for a chronic condition like HIV is to stay healthy, or to prevent illness. This
change in perspective about the medication was therefore a key element to the concept of selfefficacy for the participants of this study.
In order to build self-efficacy, the participants of this study described a process that
started with a need to accept their disease, which lead to an acceptance of the need to take
medication on a daily basis in order to control the disease and stay alive. For some, it included a
period of experimentation, to see what would happen if they took a break from taking the
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medication, or did not take it consistently, and therefore learned the hard way, after experiencing
a negative outcome to non-adherence, that they needed the medication daily. Being able to
accept that they had a chronic and fatal medical condition that required daily medication
maintenance in order to survive was therefore a transformative moment for the participants of
this study. It empowered them to prioritize their health and take their medication. Self-efficacy
therefore meant being an empowered consumer of healthcare, which according to the
participants meant that they were actively engaged in their medical care. They would actively
question their doctors about their healthcare and the medication, as well as utilize other sources
of healthcare information, including the internet, printed material, and the community-based
organizations of which they were affiliated, to study the disease and understand the science
behind the medication. Most importantly, they talked about how they were the ones in charge of
their medical care and not their doctors.
Finally, self-efficacy also meant being able to overcome the more day-to-day challenges
associated with ARV treatment adherence, such as forgetting to take the medication, traveling
with the medicine, or having to overcome the fear of HIV stigma and be able to take the
medication in public when necessary. In order to not feel tied to the medication or unable to live
an independent life with HIV, the participants developed strategies to help them remember to
take their medication, such as making it part of their daily routine, using a pill box to help them
monitor whether or not they took it on a daily basis, and using technology such as alarms or apps
on their phone to remind them to take their medication.
Motivation
The findings from this qualitative study further provided context to the complex concept
of motivation with regard to ARV treatment adherence for low-income PLWH of color. In order
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to truly overcome the multitude of competing barriers to ARV treatment adherence, the
participants talked about factors that motivated them to take their medication despite the barriers.
Not wanting to die, or wanting live, was the primary reason the participants gave to explain what
motivated them to adhere to their ARV medication. This was interrelated with the need to accept
their chronic condition and subsequent need to take medication on a daily basis in order to live,
so as not to die. Several participants talked about times in their life when they had AIDS and
were very sick. Knowing that not taking their ARV medication could cause them to get that sick
again was therefore a motivating factor to take their medication to stay healthy. Other
participants talked about the desire to be healthy in general, which included minimizing their
drug use and sexual partners, as well as adhering to their medication.
Knowing that being undetectable meant that they were unable to transmit HIV to other
people through sexual contact (U=U) was a strong motivating factor for some of the participants.
They talked about feeling liberated from the burden of having to disclose their HIV status and
free to have sex without a condom. However, others were skeptical of U=U and not ready to take
that chance or put others at risk. Finally, having a life purpose, or a goal they had yet to achieve,
was a factor that motivated the participants to take their ARV medication so that they could stay
alive long enough to achieve their goals.
Implications for the Healthcare and Social Service Industries
Points of intervention for the healthcare industry include efforts to create systems and
environments that enhance access to and trust in medical care for low-income PLWH of color.
Such efforts would be useful interventions to counter years of systemic racism and HIV stigma
in healthcare and PLWH of color’s justified mistrust of the system. Therefore, medical clinics
could focus on staff training with regard to the importance of creating a welcoming,
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nonthreatening, and inclusive environment for their patients, staffed by doctors and other
medical personal who treat their patients with respect and encourage their active engagement in
their medical care, as an equal member of the team.
Points of intervention at the structural level for the social service industry, and the field of
social work in particular, include the coordination of care for PLWH, especially since so many
have multiple chronic medical conditions in addition to HIV. This requires communicating with
all relevant medical, mental health and social service providers, and overseeing the process for
making referrals, to enhance a PLWH’s access to quality medical and mental health care and
minimize the pharmacological interactions between the prescribed medications. Coordination of
care lead by a social work team is therefore an essential component of quality and
comprehensive medical care for PLWH that helps build their trust in the system and keeps them
engaged and actively involved in the treatment.
Through psychoeducation and counseling, social workers and other mental health
providers can further help PLWH enhance self-efficacy, or their ability to prioritize their health
to take their medication. This includes the need to address the competing psychosocial and
behavioral barriers that interfere with ARV treatment adherence, such as addiction and
homelessness, by providing substance abuse/harm reduction counseling and/or treatment as well
as supportive housing for those who are homeless. Other points of intervention to address selfefficacy for low-income PLWH of color include psychosocial counseling and education around
the need to accept their disease and need to take medication to survive. This involves counseling
to empower PLWH to be actively engaged in their healthcare, so as not to feel disempowered by
their condition. Psychosocial counseling can further help PLWH focus on their motivation to
adhere to their medication, by identifying a purpose or a life goal that they have yet to achieve.
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This life goal then becomes their motivation to take their medication in order to stay alive long
enough to achieve it.
Finally, PLWH can provide peer support to other PLWH, as another point of
intervention, to help strengthen self-efficacy and motivation among vulnerable PLWH to take
their ARV treatment. This peer support may include sharing ideas that have helped them
overcome the personal barriers to ARV treatment adherence, like strategies for remembering to
take their medicine such as by making it a part of their daily routine and/or by taking it at the
same time every day. Peers can also be role models for other PLWH by taking their medication
in public in order to normalize the behavior and minimize the shame associated with the disease
and HIV stigma.
Implications for HIV Policy
Implications for HIV policy include increased attention and funding allocated to
interventions at the micro and macro level that address the complexity and multifaceted nature of
ARV treatment adherence for low-income PLWH of color. Such policy may include addressing
barriers caused by health insurance companies by regulating PLWH’s access to high quality
medical care and improving systems to streamline the bureaucracy. It may also include
regulating the training and onboarding of HIV medical providers to ensure that the provision of
HIV medical care is more culturally competent, inclusive of people’s diversity, equitable, and
less discriminatory towards PLWH. Finally, HIV policy should be addressing the social
determinants of health that impact ARV treatment adherence, and continue to monitor and work
to reduce the racial disparities in the disease and in the rates of viral suppression.
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Limitations
Limitations to this study include the fact that all of the interviews were conducted in
English and therefore the experiences of non-English speaking, low-income PLWH of color
were not included in the findings. In addition, due to the COVID-19 pandemic and the need for
social distancing, all of interviews were conducted over Zoom. Therefore, a limitation to this
study is that only those participants who had the resources, such as access to a private space to
conduct the interview, a device, and the technical capacity to participate over Zoom, were
engaged in the study. The fact that they were all stably housed at the time of the interview might
have contributed to this limitation. Therefore, the experience of currently homeless PLWH who
are virally suppressed is currently unknown. Finally, while the findings from this qualitative
study are informative for policy and practice development, there is a lack of generalizability of
the findings in a positivist, quantitative research methodological sense.
Future Research
Recommendations for future research include a study that explores the process associated
with ARV treatment with other populations of virally suppressed PLWH not included in this
study, such as non-English speaking PLWH and/or PLWH who are currently homeless. In
addition, it would be interesting to know if the ARV Treatment Adherence Model is applicable
to PLWH in general (as opposed to specifically low-income PLWH of color), or other chronic
medical conditions that require daily medication management, such as diabetes, hypertension,
and mental illness. Finally, it would be interesting to triangulate the data by testing the theory
that emerged from the qualitative study, quantitatively, to determine if there is a statistically
significant relationship between each facilitator of ARV treatment adherence (e.g., access, trust,
self-efficacy and motivation), with ARV treatment adherence, alone and combined as
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interrelated factors. Results from this quantitative study would therefore have greater external
validity and generalizability.
Conclusions
In order to end the HIV epidemic by 2030, more PLWH need to adhere to the ARV
medication treatment to achieve viral suppression. However, ARV treatment adherence is
complicated, especially for low-income PLWH of color who are disproportionately impacted by
the multitude of environmental, structural, psychosocial, behavioral and personal barriers that
impede it. This qualitative study based on Constructivist Grounded Theory engaged virally
suppressed members of this target population to unpack the process for successful ARV
treatment adherence based on the lived experience of the participants of this study. The findings
revealed a process depicted in the ARV Treatment Adherence Model. As illustrated by the
model, ARV treatment adherence is influenced by 1) access to inclusive, nonjudgmental and
destigmatizing quality medical care administered by culturally competent medical providers; 2)
trust in medical provider, the medical system, and medication; 3) self-efficacy to accept the
chronic medical condition and need to take medication to control it, be actively engaged in
medical care, and take medication as prescribed. 4) motivation, or having a will to live,
something to live for (a life goal), a desire to be healthy and not be sick, and to not transmit HIV
to others. HIV policy and medical and social service interventions designed to enhance ARV
treatment adherence for low-income PLWH of color therefore would benefit from a multifaceted
approach that addresses and integrates the facilitators of ARV treatment adherence while
minimizing the competing environmental, structural, psychosocial, behavioral and personal
barriers.
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Fig. 1. ARV Treatment Adherence Model
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Appendix B: Recruitment Flyer

The purpose of this study is to learn from
people living with HIV who are virally
suppressed about any challenges they faced
taking ARV medication and what helped them
overcome these challenges to achieve viral
suppression.

Incentives:
$20 Gift Card
+ Reimbursement for
Transportation
(if applicable)
If interested, please contact
researcher for more
information: Danielle
Strauss @ (845) 459-0409
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Appendix C: Interview Guide
Introduction:
Thank-you for agreeing to participate in my study about Antiretroviral (ARV) treatment.
As we’ve discussed, the purpose of this interview is for me to learn from you about your
experience with ARV treatment, or taking your HIV meds, which led you to become
undetectable or virally suppressed. Just so that we are clear, undetectable means that due to you
taking your HIV medication as prescribed, a lab test is unable to detect the virus in your system.
The medication is suppressing the virus, or stopping it from increasing, which is what we mean
by being virally suppressed.
The results of the study will be used to inform HIV policy and medical and social service
providers with regard to what strategies have helped people like you become virally suppressed.
Opening Questions:
1. To start off, can you tell me about how you like to get information about your health?
 If you have a question about your health, what do you do?
 Where do you go when you have a question about your health?
 Who do you go to for information about your health?
i. Friends?
ii. Family?
iii. Doctor?
iv. Someone else?
v. Somewhere else?
 How do you make decisions about your health?
2. How do you decide what to believe about healthcare?
 How do you decide what not to believe?
 Can you give me an example of a time when a friend told you something about your
health that you did not believe, or agree with?
i. What was it about what they told you that made you not believe it?
ii. What might they have said to make it more believable?
 What about a time when you read something or heard about something related to your
health in the media, say on television or an ad on the subway, that you didn’t believe?
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i. What was it about that what you read (or heard or saw) that made you not
believe it?
What about your doctor? How do you decide what to believe about things your
doctor tells you about your healthcare?
Has a doctor or medical provider ever told you something you didn’t believe?
i. What was it about what they told you that made you not believe it?
ii. What might they have said to make it more believable?
Is there anything else I should know or be asking you about with regard to what you
do to get information about your health? Your healthcare?

Key Questions:
Now I want to ask you a few questions about your medical provider
3. What has been your experience with your medical provider or providers (the doctor or
medical person or persons you go to for your HIV)?
 Do you always see the same provider?
i. If no, is there one that is your primary provider?
1. If yes, please think about this person when answering the following
questions.
2. If no, please think about all of them when answering the following
questions and try to be clear if there are distinctions between them.
ii. For the purposes of the following questions, how should I refer to this person
(e.g. provider’s name, he, she, etc.) or these people?
 What type of provider is/are ____ (e.g. doctor, nurse, PA, etc.)?
 What is it about ___________ that you like?
 Is there anything about _____ you don’t like? If so, what?
4. Have you always had the same HIV medical provider(s)?
 If no, why did you change providers?
i.
What was going on for you at the time?
5. What has been your experience with your HIV clinic?
 What is it about this clinic that you like?
 Is there anything about this clinic you don’t like? If so, what?
 Have you always been going to the same clinic?
o If no, why did you change clinics?
o What was going on for you at the time?
6. Are there other staff members at this clinic who talk to you about your HIV?
 If yes. Who?
 What have they told you?
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How important is this information from these other people, compared to what ____
has said?
How important is this information from these other people at your clinic compared to
other people in your life?

Next we are going to talk about your ARV treatment, once again, the medicine you take for
your HIV
7. What do you know about antiretroviral (ARV) treatment?
 How do you know this?
 Who first told you about ARV treatment?
 What has your doctor (or ____________) told you about ARV?
 How important is what _________ says about ARV treatment, compared to other
people in your life? Please explain.
8. What did you think the first time you were told that you need to take ARV treatment for your
HIV?
 Has your opinion about the medicine changed since then?
i. If yes, how has your opinion about ARV treatment changed over time?
1. What happened that lead you to change your opinion about the
medication?
ii. What do you think about ARV treatment today?
9. Walk me through the process of taking your medication?
 What helps you to remember to take your medication?
 What happens if you miss a pill or don’t take the medication as prescribed?
 What do you normally do in those situations?
10. What motivates you to take your medication?
 What keeps you motivated?
11. What don’t you like about the medicine?
 How do you deal with that?
12. Since you were first prescribed ARV treatment, was there ever a time when you stopped
taking your medication?
 What was going on for you at that time?
 What changed after that?
13. Is there anything else I should know, or should be asking you about your HIV meds?
The next set of questions are about Viral Suppression
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14. What have you been told about what it means to be virally suppressed?
 Who told you this?
 Do you believe what you have been told?
 If not, why not?
15. How long have you been virally suppressed?
16. Once you became virally suppressed, have you been able to maintain it?
 If yes, what do you do to maintain your virally suppressed status?
 If no, what do you think caused your viral load to go up?
i. What did you do to bring it back down?
17. Have you heard that being virally suppressed means that you cannot transmit HIV to other
people?
 What do you think about this idea?
 Do you believe it? If not, why not?
 Does knowing this factor into your decision to take your ARV medication? Please
explain.
Finally, I want to ask you some questions about challenges or struggles you may have had to
overcome in order to be able to take your HIV medication as prescribed. These are sometimes
call barriers to ARV treatment adherence.
18. What has been hard for you about taking your medication as prescribed?
 How has this changed for you overtime?
 How did you deal with these challenges?
19. Are you diagnosed with anything else besides HIV?
 If yes, how has the fact that you have this (these) other condition(s) interfered with
your ability to take your HIV medication? How so?
20. Do you or have you ever used drugs? (if not already answered above). Remember your
answers to these questions are confidential.
 If yes, how has the fact that you have this history of substance use interfered with
your ability to take your HIV medication? How so?
21. Do you have, or have you ever been diagnosed with, a mental illness? (if not already
answered above)
 If yes, how has the fact that you have this condition interfered with your ability to
take your HIV medication? How so?
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22. What else in your life has made taking your HIV medication challenging?
 Can you tell me more about that?
 How did you deal with these challenges?
Closing Questions
23. What advice would you give to other people living with HIV about ARV treatment?
24. What advice would you give to their doctors or medical providers?
 Anyone else?
25. Do you have any friends who are virally suppressed who you think would be interested in
participating in this study? If so, please give them one of these fliers and have them contact
me if they are interested.
26. Is there anything else I should know about anything we have talked about today?
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Appendix D. Code Example: Barrier to adherence - Rest of life/Overwhelming
I thought, “Who’s gonna pay for it?” Because it’s a $3,000 bottle of pills, I’m sayin’.
No, I thought, “How am I gonna manage taking it every day?”
Source: INT5EO31G.transcript

I didn't take that too well for the rest of my life that [unintelligible 17:26]. I call my
husband, and I said, "You know, once I start this treatment, I have to stay on it for
the rest of my life." And he said, "Well, you know, if it's what you have to do, do
what you have to do. It's not gonna make you sick. It should make you better." So
I kind of understand from where I was and where I am now, and that was my
decision, go ahead.
Source: INT8NN45G.transcript
I don’t like it ’cause I gotta do for the rest of my life. I don’t wanna do nothin’ for the
rest of my life, but I got so much stuff I gotta do for the rest of my life, just one
more thing added to it on the resume. When I be feeling like that, it become
overwhelming. I’m not even—
Source: INT9AG57H.transcript

I was distraught. I was devastated. 'Cause I was already on pills, but it was for
high blood pressure, hypertension. I just felt, okay, I'll have to deal with that. Then
to find that I have to do something for the rest of my life—'cause even with
hypertension, if you try to control your diet, again, exercise, I think you could get
those under manageable levels, but with HIV, it's like, that's it. It's like, once you
get diagnosed with that and you take pills, it's like, until you go in your grave, you'll
be taking pills. It was like, that thought, that drove me crazy. I was like, this is
forever. This is forever. If you want to live, it's forever. [Laughter] Yeah. That was
my mindset at the time. Yeah. It still is, actually. [Laughter]
Source: INT10GL55H.transcript

We hear about that type of medication, but you never hear about a medication
where, if you don't take this, death could be—is inevitable because your viral load
will rise, and then, of course, you could die. You could pass. They break it down,
how it affects your body and stuff. I wasn't happy about that. I felt like it could not
be done. It was unrealistic. Then, of course, the fear stepped in because I realized
that, okay, you're not gonna do this every day. It is not realistic. There are times
you're gonna forget. There are times when you're gonna get up late. You don't
want to tie yourself to this thing. That was real at first.
Source: INT13MP47F.transcript
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Appendix E. Code Example: Motivation – To Live
I feel like personal health ranks number one.
Source: INT4DS28H.transcript
Both are the same. How I act in sexual relations. I don’t want to transmit HIV. I would say
personal health and not transmitting it to other people are the same.
Source: INT4DS28H.transcript
What motivates you to take your medication? You’ve kind of already answered about what
you feel in your body, but is there anything else to add?
Interviewee: To live. To live.
Source: INT1WN33G interview
I think it's life. I want to live. I don't know what death has on the other side for me. If I keep
living, I'll know what I have to do here. I feel like I have a purpose. I'm here for a reason.
Keep living and figure out what that reason is and do it.
Source: INT2TF61A transcript
No. The way I think make people worry about us 'cause what I don't understand about life
itself, if you speak your mind, you're bad, if you don't speak your mind it's bad, so which
one do you do? Do you speak your mind and be yourself? Do you don't speak your mind
and kiss behind? [Unintelligible 01:04:35] with that. It's just like followers. I follow
everybody that's walkin' off the cliff or do I look at them and say, "No, I'm not walkin' off
the cliff. I'm goin' against what they doin' 'cause I wanna live"? That's the society we're
livin' in.
Source: INT3JJ60A.transcript
I think it was a blessing that happens, to be honest with you. I think [crosstalk 00:23:59].
Interviewer: How's that?
Interviewee: 'Cause I was livin' crazy and wild. I don't know what religion or what you
practice, but I do believe in there is a supreme being that loves you enough, that he'll give
you a choice of life or death. I chose life. In my own way, so when that happened, and I
kept tryin' to do it, and I found that the medication wasn't agreein' with me. That had to
make the biggest decision of my life. Are we still gonna party and take the med, or are we
gonna just leave the party alone and take the med?
Source: INT3JJ60A.transcript
Talk to me about that, how is the photography and your artwork? What’s your relationship
with that and your HIV? Is there a relationship?
Interviewee: Yes, it’s a big relationship, because I impress myself—I express myself with
it, and with other people. It’s been a big balance for me with my life, and doing that, and
stay in contact with people. I’m gettin’ older now, I’m 60 years old now so, it’s a different
world, and all this technology and stuff. I’m the guy that first did the first Photoshop with
scissors. [Laughter]
Interviewer: You’ve always been an artist?
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Interviewee: Yeah. Always, yeah, it gave me self being, it gave me a sense of pride.
Yeah, it helped me out a lot. It gave me a purpose, and that’s what helped me with the
HIV, and my artwork is a purpose, why you’re here on this earth. A lot of people don’t
have purposes, so I’m definitely blessed to have a purpose ‘cause I’ve seen a lot of my
friends, and people without purposes, and they die real early.
Source: INT7WB60H.transcript
Interviewer: The art has given you a purpose, and having a purpose is you think is one
of the reasons why you’re motivated to take your HIV medication?
Interviewee: Yeah, because doin’ art and my photography, I have to be alert, and to be
alert is to be aware. To be aware is to be alive. Yeah.
Interviewer: If you weren’t able to do your artwork, what do you think would happen?
Interviewee: [Laughter] I’d probably be a bum, my worsest nightmare.
Source: INT7WB60H.transcript
I think I motivate myself, like I said back to fear like, “Yeah, okay I don’t wanna die. I got
somethin’ to live for.”
Source: INT7WB60H.transcript
I always look at that dream that no matter what I go through, I’m not gonna go to that
level. It’s just some commitment I have in myself that guides me to try to do better. I can’t
do 100 percent because I don’t have 100 percent of intelligence, but I have intelligence
enough to say that I’m gon’—even drugs and alcohol won’t let me go to that level. I have
no bottom, I have a bottom ‘cause I would stop, but it’s no real bottom that I say, “Oh, this
is really bad.”
Source: INT7WB60H.transcript
Interviewer: What motivates you to get that help?
Interviewee: I don’t know. I guess when I was little, I had a dream, ‘cause I grew up in a
really bad neighborhood, and there was a lot of winos, and bums, and stuff where I was
staying, and when I was young as an adolescent, I used to tease them, and throw things
at them, and everything. Really be mean to them, until one day I have a dream that I was
a bum, and then I just stopped it. It was a nightmare that I said—it was a lifting like, “You
could be that too.” That could happen to you. I just got a change of heart, and it just
changed me.
Source: INT7WB60H.transcript
I'm okay. I'm satisfied. It's just a little pill a day, just like if I have to take my vitamin. To
stay strong, I take my medicine. I take my ARV to stay strong.
Source: INT8NN45G.transcript
Self-motivation. I start going out to the soup kitchen, the pantry, … the dinner parties, the
drink parties, the what have you, what have you, what have you. And not forget to
mention the sex parties. And I continue my daily life, taking my one day at a time. And as I
said, here I am today. I came from the worst to become strong, and I'm still striving.
Source: INT8NN45G.transcript
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Then, I don’t want to leave that responsibility on people again anyway when I could just
take my meds and keep it movin’. It's called responsibility. I’m responsible for my health.
Nobody else is gotta be responsible for me every day. When they are, when they do have
to be responsible, it’s ’cause I can’t do no more, but while I can do it, I’m gonna do
whatever I gotta do so I can have a quality of life like everybody else has, so I can walk
with some dignity. I can go out and eat with my sister like I did the other night for my
birthday. That’s what motivates me.
Source: INT9AG57H.transcript
There be times when I feel that way. I ain’t gonna lie. Very seldom that I feel that way. It’s
not really emotional choice I’m makin’, really. This is what helps your body. It’s not really
emotional choice I’m makin’ ’cause if I go on my emotion, I’m not takin’ none of this stuff.
If I go by how I feel, what I think, I wouldn’t take none of this stuff, but, like I said, I see
people who don’t take their medicine, what happens. They’re not around to tell a story. I’m
gonna tell it for ’em.
Source: INT9AG57H.transcript
Interviewer: Was there ever a time in your life where you just didn't want to take the
medication, other than the time when you were experimenting, just you didn't—you
weren't motivated?
Interviewee: I would have to say yeah, I felt that way, but—not to take it, but I still wound
up taking it because I know I have a purpose for taking it. I've already told myself, this is
what you have to do if you want to live. In my mind, I'm thinking, this is a life pill.
[Laughter] This is a life-or-death pill that you're holding in your hand. If you don't take it, if
you dent want to take it, then you decide that you want to die, that I want to die, and that's
not what I want.
Source: INT10GL55H.transcript
Definitely 'cause I want to live, first and foremost. I always say I want to—even when
sometimes I'm feeling down, I tell myself, don't you want to see your daughter walk down
the aisle? Don't you want to see—have a grandchild? Although she's 36. I'm still waiting,
but anyway. Yeah. These things. I love being here. I know for a fact that not taking it will
take me out of here, and that's something that is not even in my thought.
Source: INT10GL55H.transcript
Right. Right. I enjoy life. I enjoy living. Yeah. That's not even a question, a debate. I enjoy
living. I enjoy life.
Source: INT10GL55H.transcript
Again [crosstalk 40:16] as long as possible to see the things that I want to see, and I
like—I still have a goal this year that nobody wants to go with me. I wanted to go to the
&lt;National Park> for my birthday in April. Nobody wants to travel. That's my goal for the
year whenever I can, whenever it eases up somewhat.
Source: INT10GL55H.transcript
See, I always wanted to stop using drugs, but I never knew how. I wanted to stop, but I
couldn't. Once I found out, I guess that motivated me 'cause once I found out I was
positive, I was like, "Well, I'm gonna die anyway. I might as well try to take care of myself
now. I'm gonna die now. Now I wanna live. I don't wanna die now since I have the virus. I
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wanna live now today." That's what I'm doing now today. I'm living. I never lived before
because of the drugs. Now [unintelligible 14:44] to live 'cause I'm living today. When I was
on drugs, I wasn't living.
Source: INT11HB66F.transcript
Yes. I want to live today.
Source: INT11HB66F.transcript
Interviewer: What don't you like about having to take this medication?
Interviewee: What don't I like? Now I know I have to take it. I can't not don't like it. I have
to like it because I want to stay healthy. I wanna live today. I don't wanna die. I wanna
take care of myself the best—the way that I can today, and taking my medication every
day, I'm gonna take it every day to stay healthy.
Source: INT11HB66F.transcript
It means that I'm gonna stay healthy. I'm gonna live longer taking care of myself and I'm
gonna live as long as I'm supposed to. I don't wanna die no time soon. If I can live by
taking my medication and taking my A1C and my diabetes and my cholesterol, all that,
taking care of myself all of me, not just my HIV, but everything else that goes with it.
Source: INT11HB66F.transcript
'cause once I became positive, people would say, "Oh, you're gonna die now. Once you
get that, you got the monster. You gonna die. You gonna die real soon." I didn't want to
die, so I started taking care of myself. It had to take that because before I didn't care. I
was using drugs. I didn't care if I lived or died.
Source: INT11HB66F.transcript
He was locked up, and I wanted to live for him. I got married to him while he was in
prison, while he was in jail. I was like, “Oh.” We got married. I wanna be here for him and
do for him ‘cause we’re married now. I want him to come home and we could be one. We
could be this power couple. It didn’t work. He motivated me to do that. Then he’s
motivatin’ me now, for me to stay alive so I can prove to him that even though I’m weak at
some points, sometimes—I’m a strong person, as everybody says, but I’m not strong
because I’m sad all the time. He’s makin’ me motivate now. I’ma say he’s makin’ me
motivate to continue to take my medicine to live.
Source: INT12DM53H.transcript
I don’t like it.
Interviewer: Taking medicine.
Interviewee: I just don’t like takin’ medicine.
Interviewer: But you have to.
Interviewee: But I have to live. I have to stay alive.
Source: INT12DM53H.transcript
I wanna live. I want to live to do the things I wanted to do that I wasn’t doin’ ‘cause I was
on drugs. I got my high school diploma—
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I don’t like it. Yeah, I know that order for me to continue takin’ my medicine, it helps me
live. I have to take it regardless if it’s for the rest of my life. Even though that’s why I say I
can miss one or two doses of medicine. It’s okay, but the rest of the days, I have to take it.
Source: INT12DM53H.transcript
Now, I wanna write books. I keep sayin’ it to people, and I keep sayin’ it, and I don’t do it. I
say every time somethin’ happens, I stop to do it. That’s gonna be my one goal right
there. This year or pro’ly next year, to start my book, least one of my books.
Source: INT12DM53H.transcript
I think I want to live as long as I can, and I also want to achieve certain things for myself.
Yeah. Some changes I would like—there are things I want to experience, and there are
some changes that I want to make. I think it's all about time, wanting to be here to do it,
wanting to really live as long as—I guess, as long as I could be here, I want to be here
and attain some goals in my life.
Source: INT13MP47F.transcript
I see as an accomplishment. I feel good about that. I guess it's drugs. I hate to think about
the fact there are people who have not accomplished that. I think it gives you a reason. It
gives you a further reason to keep being healthy and to keep taking care of yourself
because with the wrong medication, making a wrong decision, you could throw that—you
could start all over again. That's something that I don't want. I feel good about it, and
that's something I try to maintain.
Source: INT13MP47F.transcript
Interviewer: Why do you take your medication?
Interviewee: ’Cause I wanna live.
Source: INT15DT35Hl.transcript
That’s right. That definitely motivates me—employment.
Source: INT15DT35Hl.transcript
I need [distorted audio 13:53].
Interviewer: Makes sense. For the recording’s sake I’m gonna say that you made a
motion with your hands about money. Is that correct?
Interviewee: Yeah. Right.
Interviewer: You need money. You need to be employed. In order to become employed
you need to keep yourself healthy. Is that right?
Interviewee: Mm-hmm.
Source: INT15DT35Hl.transcript
That I can’t really answer. I said I can’t really answer that. Why I still—it was more than a
day I miss, but I would still push myself to still take them no matter if it was for two or three
days or four. I felt that I shouldn’t be selfish. There are people that go through so much
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worse, and I got to wake up. I got to wake. I can move my fingers. I can move my fingers.
I can hear. I can see. I shouldn’t take life for granted. It’s a gift. Life’s a gift, so regardless
of that the pill is in me or not, if I’m waking up, I shouldn’t take that for granted.
Source: INT15DT35Hl.transcript
In order for me to get employment I have to be healthy.
Source: INT15DT35Hl.transcript
The more I care about living the easier it becomes.
Source: INT15DT35Hl.transcript
All time when take the medication for first time, it continue. Never stop because I need to
live long time.
Source: INT14PR54H.transcript
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